

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 15 Feb 2020 12:55:47 +0000
To: Gilman, James (NIH/CC/OD) [E]; Collins, Francis (NIH/OD) [E]; Gottesman, Michael (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Schwetz, Tara (NIH/OD) [E]
Cc: Holland, Steven (NIH/NIAID) [E]; Johnson, Alfred (NIH/OD) [E]; McGowan, Colleen (NIH/OD/ORS) [E]; Schmitt, James (NIH/OD/ORS) [E]
Subject: RE: COVID-19 messaging

[REDACTED] (b) (5)
[REDACTED]

From: Gilman, James (NIH/CC/OD) [E] [REDACTED] (b) (6)
Sent: Friday, February 14, 2020 11:32 PM
To: Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6)>; Gottesman, Michael (NIH/OD) [E] [REDACTED] (b) (6); Tabak, Lawrence (NIH/OD) [E] [REDACTED] (b) (6); Schwetz, Tara (NIH/OD) [E] [REDACTED] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: Holland, Steven (NIH/NIAID) [E] [REDACTED] (b) (6)>; Johnson, Alfred (NIH/OD) [E] [REDACTED] (b) (6); McGowan, Colleen (NIH/OD/ORS) [E] [REDACTED] (b) (6); Schmitt, James (NIH/OD/ORS) [E] [REDACTED] (b) (6)
Subject: Re: COVID-19 messaging

[REDACTED] (b) (5)

Jim

From: "Collins, Francis (NIH/OD) [E]" [REDACTED] (b) (6)>
Date: Friday, February 14, 2020 at 8:04:30 PM
To: "Gottesman, Michael (NIH/OD) [E]" [REDACTED] (b) (6)>, "Tabak, Lawrence (NIH/OD) [E]" [REDACTED] (b) (6)>, "Schwetz, Tara (NIH/OD) [E]" [REDACTED] (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6)>
Cc: "Holland, Steven (NIH/NIAID) [E]" [REDACTED] (b) (6)>, "Johnson, Alfred (NIH/OD) [E]" [REDACTED] (b) (6)>, "McGowan, Colleen (NIH/OD/ORS) [E]" [REDACTED] (b) (6), "Schmitt, James (NIH/OD/ORS) [E]" [REDACTED] (b) (6), "Gilman, James (NIH/CC/OD) [E]" [REDACTED] (b) (6)>
Subject: RE: COVID-19 messaging

This seems reasonable. [REDACTED] (b) (5)

[REDACTED]

[REDACTED] Looping in Jim Gilman.

FC

From: Gottesman, Michael (NIH/OD) [E] <[REDACTED] (b) (6)>
Sent: Friday, February 14, 2020 6:03 PM

To: Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Schwetz, Tara (NIH/OD) [E] (b) (6); Collins, Francis (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Holland, Steven (NIH/NIAID) [E] (b) (6)>; Johnson, Alfred (NIH/OD) [E] (b) (6); McGowan, Colleen (NIH/OD/ORS) [E] <(b) (6)>; Schmitt, James (NIH/OD/ORS) [E] <(b) (6)>
Subject: COVID-19 messaging

We have had many requests for additional guidance concerning staff potentially exposed to COVID-19. OMS has prepared the attached message which has been reviewed by Steve Holland and HR. The intent is to send this from OMS to all hands.
Michael

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 15 Feb 2020 02:23:37 +0000
To: Holland, Steven (NIH/NIAID) [E]
Subject: RE: COVID-19 messaging
Attachments: COVID-smh - with Fauci edits.docx

Steve:

See my tracked edits.

(b) (5)

(b) (5)

Thanks,
Tony

From: Holland, Steven (NIH/NIAID) [E] (b) (6) >
Sent: Friday, February 14, 2020 9:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW: COVID-19 messaging

Tony,

Could you please look at the attached and make any edits you think would help.

(b) (5)

(b) (5)

Steve

--

Director, Division of Intramural Research
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bldg. 10/11N248 MSC 1960
Bethesda, MD 20892-1960

(b) (6) voice

301-480-4507 fax

(b) (6) email

Assistant lab: Eva Portillo

(b) (6) email

(b) (6) voice

Assistant to SD: Beth Schmidt

(b) (6)

(b) (6) voice

From: "Gottesman, Michael (NIH/OD) [E]" (b) (6) >
Date: Friday, February 14, 2020 at 6:12 PM
To: "Schmitt, James (NIH/OD/ORS) [E]" (b) (6)
Cc: "Moss, Bradley (NIH/OD/ORS) [E]" (b) (6), Steven Holland
(b) (6)
Subject: Re: COVID-19 messaging

(b) (5)

. This can wait until next week.
Michael

From: "Schmitt, James (NIH/OD/ORS) [E]" (b) (6)
Date: Friday, February 14, 2020 at 6:07 PM
To: "Gottesman, Michael (NIH/OD) [E]" <(b) (6)>
Subject: FW: COVID-19 messaging

I meant to copy you on this Michael. Jim

From: Schmitt, James (NIH/OD/ORS) [E]
Sent: Friday, February 14, 2020 6:07 PM
To: Moss, Bradley (NIH/OD/ORS) [E] (b) (6); Bailin, Heike
(b) (6)
Cc: Newcomer, Derek (NIH/OD/ORS) [E] (b) (6)
(b) (6); Wheeland, Daniel (NIH/OD/ORF) [E] (b) (6);
McGowan, Colleen (NIH/OD/ORS) [E] (b) (6); Tosten, Timothy
(NIH/OD/ORS) [E] <(b) (6)>
Subject: FW: COVID-19 messaging

Hi Brad,

It sounds like Dr. Gottesman wants this sent from OMS to everyone.

I don't know how to do that. Can you help us with this and how soon can it be sent?

I'm heading out of town and won't return to the clinic until Tuesday. Dr. Bailin will be in charge of OMS in my absence.

Jim

James M. Schmitt, M.D., M.S.
Medical Director
Occupational Medical Service, DOHS

National Institutes of Health
10 Center Drive
Bethesda, MD 20892-1584

(b) (6)

From: Gottesman, Michael (NIH/OD) [E] <(b) (6)>
Sent: Friday, February 14, 2020 6:03 PM
To: Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Schwetz, Tara (NIH/OD) [E] (b) (6); Collins, Francis (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Holland, Steven (NIH/NIAID) [E] (b) (6)>; Johnson, Alfred (NIH/OD) [E] (b) (6); McGowan, Colleen (NIH/OD/ORS) [E] (b) (6)>; Schmitt, James (NIH/OD/ORS) [E] (b) (6)>
Subject: COVID-19 messaging

We have had many requests for additional guidance concerning staff potentially exposed to COVID-19. OMS has prepared the attached message which has been reviewed by Steve Holland and HR.

The intent is to send this from OMS to all hands.

Michael

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 15 Feb 2020 02:08:57 +0000
To: Casetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Marston, Hilary (NIH/NIAID) [E]; Eisinger, Robert (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]
Subject: RE: Rapid instrument-free NAAT for COVID-19
Attachments: VisbyMedical_TechWatch_Feb2020_nCoV_NIH.pdf

See attachment as per prior e-mail.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Friday, February 14, 2020 9:08 PM
To: Gary K. Schoolnik <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] <(b) (6)>; Marston, Hilary (NIH/NIAID) [E] <(b) (6)>; Eisinger, Robert (NIH/NIAID) [E] <(b) (6)>; Lerner, Andrea (NIH/NIAID) [E] <(b) (6)>; Casetti, Cristina (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Rapid instrument-free NAAT for COVID-19

Gary:

Thanks for the note. I would be happy to discuss this with you. Please have your office contact my Special Assistant, Patty Conrad, (copied here) to set up a mutually convenient time when we can chat.

Best regards,
Tony

From: Gary K. Schoolnik <(b) (6)>
Sent: Friday, February 14, 2020 6:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Adam de la Zerda <(b) (6)>
Subject: Rapid instrument-free NAAT for COVID-19

Dear Tony,

In addition to my role as a Stanford Medical School professor, I am the Chief Medical Officer of Visby Medical, a relatively new Silicon Valley diagnostics company focused on rapid detection of infectious agents. Visby Medical has developed a rapid (~25 min sample-to-answer) palm-sized, 40 cycle PCR (or RT-PCR) single-use device that does not require an instrument; it is used once, and then discarded or recycled. (b) (4)

(b) (4)
The device is stable at room temperature for up to two years and thus it could be deployed widely.

We are seriously considering using this platform to develop a rapid test to detect COVID-19. Proof of principles that have been achieved toward that end are our demonstration that the device can use two-step RT-PCR to detect influenza A and B in NP swab samples. The main features of the device are described in the brief accompanying PDF.

I write now because we are unsure, if we were to produce a COVID-19 device, how it would be deployed, by whom it would be used and who might be willing to purchase it. I would be very grateful if you might be able to speak briefly with me and my colleagues about these open questions. I am convinced this device can meet a major unmet need in clinical care and disease control for this epidemic and we, as a group, want to make a difference. Your advice would be invaluable as we weigh the risks and benefits of pivoting the company to this application.

With all best wishes; I hope all is well with you and your family.

gary

Gary Schoolnik, M.D.
Professor of Medicine
Stanford Medical School
Attending Physician (Internal Medicine, Infectious Diseases)
Stanford University Hospital
Chief Medical officer
Visby Medical

From: (b) (6)
Sent: Fri, 14 Feb 2020 18:45:53 -0500
To: Julia Belluz
Subject: Re: call

My pleasure!

On Feb 14, 2020, at 6:10 PM, Julia Belluz <julia.belluz@vox.com>wrote:

Thank you so much for making the time to comment at what I know is a crushingly busy time. As usual don't hesitate to ping if you have any further comments or questions! Julia

<https://www.vox.com/2020/2/14/21134473/coronavirus-outbreak-singapore-us-symptoms-pandemic>

Sent from my iPhone

On Feb 14, 2020, at 1:21 PM, Fauci, Anthony (NIH/NIAID) [E]
<(b) (6)>wrote:

Julia:

I just called you now (7:20 AM Washington, DC time) and got mvoice mail in German that I could not understand. You can call me at (b) (6)

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or

any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 21:09:40 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Your Expertise requested/COVID-19 Forum

OK. Let us discuss. As long as it is remote...

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Friday, February 14, 2020 3:45 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: Your Expertise requested/COVID-19 Forum

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Roache, Christina <[REDACTED] (b) (6)>
Sent: Friday, February 14, 2020 3:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Your Expertise requested/COVID-19 Forum

Dear Dr. Fauci,

You have been kind enough to be a panelist on our [Forums at the Harvard T.H. Chan School of Public Health](#), and I wanted to see if you were available to participate remotely in a Forum that we are organizing on **March 2** about **COVID-19**.

The Forum will live stream on the websites of The World and The Forum, as well as on Facebook and YouTube.

The World will send a journalist to moderate and co-promote.

The Forum is called "**The Coronavirus Outbreak: Tracking COVID-19**", presented jointly with **The World from PRX & WGBH**.

Should you agree to participate, we ask that you join us remotely from **11:40am-1pm ET on March 2**; the actual live webcast will be noon-1pm ET.

We have been active in covering this outbreak. We did a [highly successful Facebook Live Q&A](#) last week and are doing another Q&A next week.

As a reminder, Forum webcasts are one-hour long and are panel discussions, typically with 3-4 panelists, plus a moderator. As noted, these discussions are live streamed from our Leadership Studio at our school in front of a studio audience (about 40 seats) and an online audience. Anyone with an Internet connection can watch the live webcasts; no registration or fee is required.

Previous speakers in The Forum series have included Gina McCarthy, former EPA Administrator; Anthony Foxx, then U.S. Secretary of Transportation; Eric Holder, then U.S. Attorney General; Kathleen Sebelius, then U.S. Secretary of Health and Human Services; Gordon Brown, former UK Prime Minister; as well as numerous former governors and key public health policymakers and officials from a range of public and private sector entities.

The Forum live webcasts are also streamed on The Forum website, where they are accompanied by a live chat and online commenting, and on Facebook and YouTube. These webcasts are later posted as on-demand videos to our site and to Harvard's YouTube and iTunesU channels. We also make available podcasts, transcripts and other materials. Collectively, the programs and complementary content have resulted in nearly five million viewer engagements so far, and our website has received visits from more than 200 countries and territories and every U.S. state.

Please share your thoughts when you are able.

Cheers,

Christina Roache
Associate Director, Production and Web, The Leadership Studio
Harvard T.H. Chan School of Public Health

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 20:23:04 +0000
To: Clayton, Janine (NIH/OD) [E]
Subject: RE: Sex differences in COVID-19

Not much at this point. [REDACTED] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Clayton, Janine (NIH/OD) [E] <[REDACTED] (b) (6)>
Sent: Friday, February 14, 2020 3:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Sex differences in COVID-19

Hi Tony,
[REDACTED] (b) (5)

Janine

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 20:21:51 +0000
To: Richard Allen Johnson
Subject: RE: 2020.02.14 Friday

Dick:

Thanks for the note. I certainly appreciate your concerns about WHO. Not much sleep for me lately. Just like internship.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Richard Allen Johnson (b) (6)
Sent: Friday, February 14, 2020 3:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Richard Allen Johnson (b) (6)
Subject: 2020.02.14 Friday

Hi, Tony,

I am very distressed by the Face of the WHO. Their public face, their news updates, are of the quality of those of a third world country. I only hope that they function better than their news updates suggest. They need a world class public relations firm.

I am deeply concerned re Covid-19 in India (with a population of 1500 million) and Africa (population 100 million). News reports do not mention anything of this pandemic waiting to happen.

Hope that you are well and getting a good night's rest.

Best,
Dick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 18:27:24 +0000
To: Casseti, Cristina (NIH/NIAID) [E]
Subject: FW: inhaled buformin for coronavirus
Attachments: [REDACTED] (b) (4)

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Steven Lehrer [REDACTED] (b) (6) >
Sent: Friday, February 14, 2020 1:17 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >; Erbeling, Emily (NIH/NIAID) [E]
[REDACTED] (b) (6) >
Subject: [REDACTED] (b) (4) for coronavirus

Dr. Fauci,

[REDACTED] (b) (4)

Steven Lehrer, MD

[REDACTED] (b) (4)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 17:39:33 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject: RE: for review: proposed responses for Italian media request

Nice Job. I have made one minor edit in the first response. Otherwise, it is ready to go. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6) >
Sent: Friday, February 14, 2020 12:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Billet, Courtney (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Subject: for review: proposed responses for Italian media request

Dr. Fauci –

This is not urgent for today. A reporter from the Italian health website Pazienti.it reached out to you directly with questions about coronavirus vaccine development. I have drafted proposed responses for your review attached and pasted below. I will send the final responses to the reporter attributed to you.

Coronavirus vaccine: when will it be available? What are the difficulties?

The National Institutes of Health is on track to test an experimental messenger RNA (mRNA) vaccine in a Phase 1 clinical trial this spring. This first phase of clinical testing will involve giving the vaccine to healthy adults in the United States to see if it is safe and if it can induce an immune response in recipients. It is important to realize that the development of investigational vaccines and the clinical testing to establish their safety and effectiveness takes time. A vaccine against the novel coronavirus will likely not be widely available for at least a year.

Could the Coronavirus mutate, if a vaccine cannot be found in time?

We are learning more about the novel coronavirus every day. At this time, we are not aware of any mutations that might affect vaccine development. Based on our experience with other coronaviruses, including SARS-CoV and MERS-CoV, it is unlikely—but not impossible—that the novel coronavirus will mutate in a way that would have an impact on the development of medical countermeasures. We are continuing to monitor this.

Will the vaccine be the solution against Coronavirus?

A safe and effective vaccine would be an extremely valuable tool to help stop the spread of infection and prevent future outbreaks. However, proven public health practices of identifying cases, isolating patients, and tracing contacts must continue alongside a vaccination program.

Thanks,

Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892

Direct: (b) (6)

(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 17:23:43 +0000
To: Casseti, Cristina (NIH/NIAID) [E]
Subject: FW: [REDACTED] (b) (4)

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hardham, John M [REDACTED] (b) (6) >
Sent: Friday, February 14, 2020 9:15 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: [REDACTED] (b) (4)

Tony:

It was good to see you again at the ASM Biothreats Conference. We had worked together on the Medical Countermeasure Initiative when I was the Medical Officer for the DOD Chem Bio Program (under ASD Andrew Weber) several years ago.

[REDACTED] (b) (4)

If you or your staff have any interest, please feel free to reach out to me.

Hope you have a wonderful day!

John

John M. Hardham, Ph.D. | Research Director, Global Biologics Research
Director, Zoetis Center for Transboundary and Emerging Diseases

Zoetis | 333 Portage Street, KZO-300-204.3, Kalamazoo, MI 49007

Office: (b) (6) | Mobile: (b) (6) | (b) (6)

Visit Us: zoetis.com

zoetis

FOR ANIMALS. FOR HEALTH. FOR YOU.

Emerging Infectious Diseases
First to know...Fast to market

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 15:52:49 +0000
To: Strauss, Nicole
Cc: Mascola, John (NIH/VRC) [E];Graham, Barney (NIH/VRC) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: [REDACTED] (b) (4) | [REDACTED] (b) (4)

Nicole:

Thank you for your note and interest. I will copy on this e-mail Drs. John Mascola and Barney Graham of our Vaccine Research Center who are developing the vaccine with Moderna so that they can respond directly to you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Strauss, Nicole [REDACTED] (b) (6)
Sent: Friday, February 14, 2020 10:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Cc: Weisser, Karen [REDACTED] (b) (6)
Subject: [REDACTED] (b) (4) | [REDACTED] (b) (4)

Dear Dr. Anthony Fauci,

[REDACTED] (b) (4)

Best regards,
Nicole



Nicole Strauss

Pipeline Development & Innovation Lead

T: (b) (6) | M: (b) (6)

500 Arcola Road, Collegeville, PA 19426

[Website](#) | [LinkedIn](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 14:22:00 +0000
To: Greg Folkers ([REDACTED] (b) (6))
Subject: NEJM
Attachments: NEJM Editorial - Fauci et al -1st draft - 02-13-2020.docx, nejmoa2001316.pdf

Here it is.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 03:20:06 +0000
To: Embry, Alan (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Institutional request for information

Thanks, Alan.

From: Embry, Alan (NIH/NIAID) [E] (b) (6)
Sent: Thursday, February 13, 2020 10:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Fried, Linda P. (b) (6); Redfield, Robert R. (CDC/OD) (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Goldman, Lee (b) (6); Booth, Jane (b) (6); Katznelson, Ira I. (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E] (b) (6)
Subject: RE: Institutional request for information

Dear Dr. Fried,

Answers to your questions are below.

1. Is the CDC or NIH overseeing the distribution of the live virus in the U.S.?

There is an interagency working group convened by the Assistant Secretary for Preparedness and Response overseeing samples, and NIH and CDC are central to this. Virus is being deposited in BEI Resources (a NIAID contract resource) for characterization, growth and distribution. The WA isolate is available now and a Hong Kong isolate may be added soon.

2. Will you be the sole source of distribution in the U.S., or will institutions be permitted to obtain it directly from other sources?

Assuming appropriate permits are in place, there is no limitation on an institution obtaining samples directly from BEI or other sources. In a public health emergency, the U.S. government seeks to make isolates available under a Simple Letter Agreement that does not impose IP restrictions on academics or developers (see attached language).

3. If it can be obtained from other sources, what sources will be permitted? For example, the China or Hong Kong CDC or University of Hong Kong?

Assuming appropriate permits and safety controls, there is no limitation on from where samples can be obtained. However, there may be intellectual property restrictions from some sources and your technology transfer office would need to negotiate if requested directly.

4. If you are to be the sole source, when would you expect to have a process for considering requests?

BEI resources already has a process for sharing in place and is currently sharing the viral isolate obtained from the first Washington case. NIAID anticipates that other viral isolates will be obtained soon, and BEI is committed to making those available to the scientific community as soon as

possible. We (NIAID/ USG) do not expect to be the only source, but will likely be one of the main sources for this research resource based on experience with Zika.

5. If someone wishes to travel to China to work on the live virus, are there any travel restrictions other than the self isolation/quarantine already in place (and of course subject to change over time)?

For that, contacting CDC directly would make sense. If you would like us to inquire, we can. For high consequence viruses, use of proper PPE has been a mitigating factor in quarantine consideration.

Please feel free to contact me if you have additional questions.

Thanks,
Alan

Alan Embry, Ph.D.
Chief, Respiratory Diseases Branch
Division of Microbiology and Infectious Diseases, NIAID, NIH
5601 Fishers Lane, Room 8E31
Rockville, MD 20892

(b) (6)

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Thursday, February 13, 2020 6:35 PM
To: Fried, Linda P. (b) (6); Redfield, Robert R. (CDC/OD) (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Goldman, Lee (b) (6); Booth, Jane <(b) (6)>; Katznelson, Ira I. (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Embry, Alan (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E] (b) (6)
Subject: RE: Institutional request for information

Linda:

There is a "sample sharing" working group involving NIH and CDC. I have copied both Hilary Marston and Alan Embry from NIAID who are involved in this group and will ask them by this e-mail to respond to items #1 through 4. Regarding returning travelers from China (item #5) if in Wuhan (Hubei province) within previous 14 days, they submit to institutional quarantine; if in non-Hubei province part of China, then they face self-isolation.

Hope that this is helpful.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fried, Linda P. (b) (6)
Sent: Thursday, February 13, 2020 12:45 PM
To: Redfield, Robert R. (CDC/OD) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Goldman, Lee (b) (6); Booth, Jane (b) (6); Katznelson, Ira I. (b) (6)
Subject: Institutional request for information

Dear Drs. Redfield and Fauci,

I am writing on behalf of Columbia University, which has received a request from Dr. Ian Lipkin to transfer live novel coronavirus from Hong Kong to his BSL3 facility at the University. As we evaluate his request, we note that he has approval from a CDC official to import the virus (see attached). However, as we consider the risks and benefits of Dr. Lipkin's proposal, we ask the two of you:

1. Is the CDC or NIH overseeing the distribution of the live virus in the U.S.?
2. Will you be the sole source of distribution in the U.S., or will institutions be permitted to obtain it directly from other sources?
3. If it can be obtained from other sources, what sources will be permitted? For example, the China or Hong Kong CDC or University of Hong Kong?
4. If you are to be the sole source, when would you expect to have a process for considering requests?
5. If someone wishes to travel to China to work on the live virus, are there any travel restrictions other than the self isolation/quarantine already in place (and of course subject to change over time)?

Thank you very much for your help with these important questions as we all try to do our best to contribute solutions to this health crisis.

With best regards,
Linda

Linda P. Fried, M.D., M.P.H.
Dean and DeLamar Professor of Public Health
Professor of Epidemiology
Mailman School of Public Health
Professor of Medicine, Vagelos College of Physicians and Surgeons
Senior Vice President, Columbia University Irving Medical Center
Columbia University

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 03:00:23 +0000
To: Mansoura, Monique K.
Cc: Conrad, Patricia (NIH/NIAID) [E]; Andrew W Lo; Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: A proposed solution to finance COVID-19 vaccines - Introducing MIT's Professor Andrew Lo

Thanks, Monique. Please have Andrew send the proposal to Cristina Cassetti (copied here) and she can then brief me on it.

Best,
Tony

From: Mansoura, Monique K. (b) (6) >
Sent: Thursday, February 13, 2020 10:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Andrew W Lo <(b) (6)>
Subject: A proposed solution to finance COVID-19 vaccines - Introducing MIT's Professor Andrew Lo

Dr. Fauci,

The nation again is fortunate to have your leadership for this latest public health emergency. Thank you for all you are doing. I know you are extraordinarily busy, so I'll be brief.

I want to introduce you to [MIT Sloan Professor Andrew Lo](#), a world leader in healthcare finance who has focused much of his work recently on accelerating biomedical innovation via novel financing structures. I have worked with him to explore financial engineering approaches to establish more durable public-private partnerships for medical countermeasures. The persistent challenges you articulated at the Aspen Institute event this week resonate loudly with Andrew and me.

He has proposal for COVID-19 that he would like to present to you. I defer to him to provide further information.

Respectfully,
Monique

MONIQUE K. MANSOURA, PH.D., M.B.A.

Executive Director, Global Health Security and Biotechnology

The MITRE Corporation

202 Burlington Road | Bedford, MA | 01730-1420

Office: (b) (6)

Mobile: (b) (6)

Email: (b) (6)

The MITRE Corporation is a not-for-profit organization that operates federally funded research and development centers for the United States government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 02:56:17 +0000
To: Greg Folkers ([REDACTED] (b) (6))
Subject: FW: FYI -- images of SARS-CoV-2 now up

Let us make some power point slides from these. Thanks.

From: Billet, Courtney (NIH/NIAID) [E] ([REDACTED] (b) (6))>
Sent: Thursday, February 13, 2020 1:22 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FYI -- images of SARS-CoV-2 now up

<https://www.niaid.nih.gov/news-events/novel-coronavirus-sarscov2-images>
<https://www.flickr.com/photos/niaid/albums/72157712914621487>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 02:42:53 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Greg Folkers [REDACTED] (b) (6)
Subject: FW: PBS'S FIRING LINE REQUEST // DR. ANTHONY S. FAUCI

Patty: Let us discuss.

Greg: Are they a big deal?

From: Melanie Starling <melanie@thedocumentarygroup.com>
Sent: Thursday, February 13, 2020 6:39 PM
To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Fauci, Anthony (NIH/NIAID) [E]
<[REDACTED] (b) (6)>
Subject: PBS'S FIRING LINE REQUEST // DR. ANTHONY S. FAUCI
Importance: High

Good Evening,

Please see below for Dr. Anthony S. Fauci for [PBS'S FIRING LINE WITH MARGARET HOOVER](#).

Due to a last minute cancellation, we are crashing on a deadline and need to know if he is able to join us ASAP.

I look forward to hearing your thoughts and all best,
Melanie

Melanie Starling

Firing Line with Margaret Hoover

Cell: + [REDACTED] (b) (6)

Email: melanie@thedocumentarygroup.com



Good Evening,

This is Melanie Starling writing on behalf of *PBS'S FIRING LINE WITH MARGARET HOOVER*.

FIRING LINE is the rare program in the political landscape that seeks a rigorous and earnest exchange of ideas, with the luxury to let the conversation breathe. Margaret has brought back the spirit of this venerated show, which aired from 1966 to 1999, that is lacking in today's polarized cable news ecosystem – at a time when we need it more than ever. One guest. 30 minutes. Airing to a thoughtful and engaged *PBS* audience.

We would be honored to have Dr. Anthony S. Fauci join *Firing Line* for an interview.

Dr. Fauci has dedicated his career to understanding, preventing, and protecting people across the globe from infectious diseases, which is why we would be so honored to share our stage with him at this time. As the coronavirus continues to spread, we are interested in better understanding the deadly virus the world is racing to contain. Equally, we are interested in highlighting any other public health issues or policies close to Dr. Fauci's heart. Most importantly, with our program, we have the luxury of time – where we can truly delve into these issues in a substantive, nuanced manner that is missing in much of today's 24-hour news cycle.

THE DETAILS FOR TAPING

TAPE DATE: TARGETING FEBRUARY 19TH – EVENING TAPING IS PREFERRED

TAPE TIME: 45 MINUTES

LOCATION: NYC (WNET STUDIOS NEAR LINCOLN CENTER)

TRAVEL, HAIR, & MAKE-UP IS PROVIDED ON REQUEST.

FIRING LINE is carried nationwide on *PBS* with 99% market pick-up, and is suggested programming for *PBS*'s 8:30 PM ET on Friday nights with multiple airings through the week. On Twitter, we have a growing 2.9M+ monthly impressions. Equally, as you know, *PBS* remains a coveted home for intellectual, elevated programming – and stands out as a **top 5 outlet to reach persuadable voters**.

HIGHLIGHT REEL

FIRING LINE is produced by the **Oscar-nominated Tom Yellin** at The Documentary Group.

Please reach out to me if there is any interest. We will bend over backwards to get it done.

Thank you in advance for your consideration, and please feel free to reach out to me 24/7 with questions or concerns.

All the best,

Melanie

Melanie Starling

Firing Line with Margaret Hoover

Cell: [REDACTED] (b) (6)

Email: melanie@thedocumentarygroup.com

ABOUT FIRING LINE WITH MARGARET HOOVER

Firing Line with Margaret Hoover is a refreshing reprisal of William F. Buckley's iconic PBS program, a smart, civil and engaging contest of ideas. The series maintains the character of the original, providing a platform that is diligent in its commitment to civility and the rigorous exchange of opinion. *Firing Line with Margaret Hoover* comes at a time when meaningful discourse is needed more than ever. Interviews and debates will highlight leading lights from the left and right, complemented by archival footage from the original *Firing Line* to remind viewers of longstanding conservative and liberal arguments, where they've been disproved or reinforced over time. It is an opportunity to engage in the debate about the America that we want to create for the 21st century — and summon Americans of every political persuasion to a rigorous examination of the choices we must make together in the challenging years ahead. Showrunner is Emmy, Dupont and Murrow-winning producer Alyssa Litoff.

ABOUT MARGARET HOOVER

Margaret Hoover is an American political commentator. In addition, she is also an author, feminist, and gay rights activist. Currently, she works as a political commentator for CNN.

HIGHLIGHTS ON FIRING LINE WITH MARGARET HOOVER

[Speaker Paul Ryan](#), [Sen. Ben Sasse \(R-NE\)](#), [Gov. Chris Christie](#), [Gov. Mitch Daniels](#), [Gov. John Kasich](#), [Gov. Scott Walker](#), [Rep. Alexandria Ocasio-Cortez \(D-NY\)](#), [Rep. Eric Swalwell \(D-CA\)](#), [Stacey Abrams](#), [Donna Brazile](#), [Gretchen Carlson](#), [Caitlyn Jenner](#), [Christine Lagarde](#), [Peter Navarro](#), [Oliver North](#), [Andrew McCabe](#), [Tom Steyer](#), [H.R. McMaster](#), [Rep. Tulsi Gabbard](#), [Ann Coulter](#), [Tony Blair](#), [José Andrés](#), [Rep. Liz Cheney \(R-WY\)](#), [Rep. Jim Clyburn \(D-SC\)](#), [Rep. Pramila Jayapal \(D-WA\)](#), [Sen. Ted Cruz \(R-TX\)](#), [Gen. Jim Mattis](#), [Condoleezza Rice](#), [Andrew Yang](#), [Michael Bloomberg](#), [Michael Moore](#), [Paul Krugman](#), [Amb. Nikki Haley](#), [Adam Schiff \(D-CA\)](#)

Melanie Starling

PBS's *Firing Line with Margaret Hoover*

Cell: + [REDACTED] (b) (6)

Email: melanie@thedocumentarygroup.com



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 02:36:46 +0000
To: ncalio@airlines.org
Cc: Conrad, Patricia (NIH/NIAID) [E]; Redfield, Robert R. (CDC/OD); Cetron, Marty (CDC/DDID/NCEZID/DGMQ)
Subject: FW: Coronavirus Task Force
Attachments: Fauci A4A Letter to Coronavirus Task Force .pdf

Nick:

Many thanks for sending this. The CDC would be very interested in your willingness to move in the direction of having complete contact information on passengers available to them. I am copying CDC Director Bob Redfield and his CDC colleague Marty Cetron on this e-mail. I am sure that one of them will contact you about this issue.

Best regards,
Tony

From: Calio, Nicholas <ncalio@airlines.org>
Sent: Thursday, February 13, 2020 8:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Coronavirus Task Force

Dear Dr. Fauci,

Please see the attached letter.

Thank you,

Nick Calio

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 14 Feb 2020 02:09:44 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Invitation: 388393 Santos (Coronavirus Preparedness Workshop)

Tell them that I turned down the same invitation and he should turn it down also. It is not a major event

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Thursday, February 13, 2020 8:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Subject: FW: Invitation: 388393 Santos (Coronavirus Preparedness Workshop)

Please see below. You were invited to this – it was discussed in our daily meeting and we decided to decline it for you. we did decline it. would you recommend the same as they are now asking Dr Collins.

Pls advise.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Harris, Kara (NIH/NIAID) [E] (b) (6) >
Sent: Wednesday, February 12, 2020 4:18 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6) >; Haskins, Melinda (NIH/NIAID) [E] (b) (6)
Subject: Invitation: 388393 Santos (Coronavirus Preparedness Workshop)

Hi, Patty -

Exec Sec would like Dr. Fauci's opinion on whether Dr. Collins should accept the attached invitation to speak at an upcoming Coronavirus Preparedness Summit & Workshop being held this June in Washington, DC. The conference is being organized by Syllabusx, a group of "international specialists in public health and emergency planning events and disaster recovery conferences."

Given the nature of the conference topics, do you concur with recommending Dr. Collins decline the invitation and refer to CDC?

Thanks for your input.

Kara

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 13 Feb 2020 23:22:27 +0000
To: Alison Galvani
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Lancet special issue proposal

Alison:

Thanks for the note. I really appreciate your kind invitation, but unfortunately, I will have to decline. My plate is already overflowing and I just cannot take on any additional editorial responsibilities. In addition, I am swamped with coronavirus "stuff" that is not going to end soon. I hope that you understand.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alison Galvani (b) (6)
Sent: Wednesday, February 12, 2020 2:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Lancet special issue proposal

Hi Tony,

I hope you are well.

(b) (4)

Thank you so much for your consideration.

Warmest regards,
Alison

--
Alison Galvani, PhD

Director, Yale Center for Infectious Disease Modeling and Analysis (CIDMA)
Burnett and Stender Families Professor of Epidemiology
Yale School of Public Health
Yale School of Medicine
New Haven, CT 06520

(b) (6)
<http://cidma.yale.edu/>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 13 Feb 2020 23:10:07 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Personal connection

Please set this up (5 minutes) for Monday.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 12, 2020 8:58 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: Personal connection

This guy called last night and seemed to know you – let me know if and where you want me to direct him.

Or maybe do a call with you on a quieter day - Monday on Pres day holiday?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Banner, Jon {PEP} <(b) (6)>
Sent: Tuesday, February 11, 2020 9:44 PM
To: (b) (6) Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Personal connection

Dear Dr. Fauci,

Jon Banner here. You may remember me from my days at ABC News, where I was Executive Producer of World News Tonight with Peter Jennings, Charlie Gibson, and Diane Sawyer. I was also Executive Producer of This Week with George Stephanopoulos and early on I was [George Strait](#)'s producer. Back then, you were the most engaging, eloquent guests on the subject of HIV/AIDS and other life and death issues of our time, and your input was of enormous value to our viewers and the general public.

Today, I am President of the PepsiCo Foundation and EVP of Global Communications for the company. I was hoping you could help us identify an expert to provide similar insight and analysis for our company as we deal with the impact of the Wuhan coronavirus. While we would of course welcome your counsel, I recognize that you have a full plate of critical responsibilities with NIH and don't want to take up too much of your time.

If you have a few minutes for a quick call, I'd love to get your take and catch up. If not, I would deeply appreciate it if you could connect me with another expert over email.

Thanks very much, and hope you are doing well!

Warm regards,

Jon

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 13 Feb 2020 22:47:23 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Institutional request for information
Attachments: CII 2020 CDC import permit.pdf

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fried, Linda P. (b) (6)
Sent: Thursday, February 13, 2020 12:45 PM
To: Redfield, Robert R. (CDC/OD) (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Goldman, Lee
(b) (6); Booth, Jane (b) (6); Katznelson, Ira I.
(b) (6)
Subject: Institutional request for information

Dear Drs. Redfield and Fauci,

I am writing on behalf of Columbia University, which has received a request from Dr. Ian Lipkin to transfer live novel coronavirus from Hong Kong to his BSL3 facility at the University. As we evaluate his request, we note that he has approval from a CDC official to import the virus (see attached). However, as we consider the risks and benefits of Dr. Lipkin's proposal, we ask the two of you:

1. Is the CDC or NIH overseeing the distribution of the live virus in the U.S.?
2. Will you be the sole source of distribution in the U.S., or will institutions be permitted to obtain it directly from other sources?
3. If it can be obtained from other sources, what sources will be permitted? For example, the China or Hong Kong CDC or University of Hong Kong?
4. If you are to be the sole source, when would you expect to have a process for considering requests?

5. If someone wishes to travel to China to work on the live virus, are there any travel restrictions other than the self isolation/quarantine already in place (and of course subject to change over time)?

Thank you very much for your help with these important questions as we all try to do our best to contribute solutions to this health crisis.

With best regards,
Linda

Linda P. Fried, M.D., M.P.H.
Dean and DeLamar Professor of Public Health
Professor of Epidemiology
Mailman School of Public Health
Professor of Medicine, Vagelos College of Physicians and Surgeons
Senior Vice President, Columbia University Irving Medical Center
Columbia University

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 13 Feb 2020 22:44:12 +0000
To: Stoffels, Paul [JJCUS]
Cc: Riccobene, Kim [JJCUS]; Van Hoof, Johan [JRDBE]; Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]; Eisinger, Robert (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]; Mascola, John (NIH/VRC) [E]; Erbelding, Emily (NIH/NIAID) [E]
Subject: RE: COVID-19 vaccine development

Paul:

Thanks for the note. I will have Patty Conrad (copied here) try to work something out for Feb. 21st. My schedule is at the mercy of the White House and the Congress and so I cannot guarantee anything right now.

Best Regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stoffels, Paul [JJCUS] (b) (6) >
Sent: Thursday, February 13, 2020 9:42 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6) >
Cc: Riccobene, Kim [JJCUS] (b) (6); Van Hoof, Johan [JRDBE] (b) (6) >
Subject: COVID-19 vaccine development

Dear Tony,

Four weeks ago our team kicked off the experimental work on the development of a COVID-19 - vaccine.

(b) (4)

(b) (4)

If you have time for a meeting on the 21st in the afternoon or a call in the course of the next 10 days, I would much very appreciate.
Feel free to call me or have you assistant connect with my assistant Kim Riccobene to set up a call. I will be in Europe till the 19th.

Best regards,

Paul

Paul Stoffels, MD
Vice Chairman & CSO
Johnson & Johnson

(b) (6)
(Mobile Europe)
(Office US)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 13 Feb 2020 03:16:08 +0000
To: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Run of show - 2/13, 9-10am White House Roundtable on COVID-19

Make sure that this is in my folder.

From: Selgrade, Sara (NIH/NIAID) [E] (b) (6)>
Sent: Wednesday, February 12, 2020 3:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; Conrad, Patricia (NIH/NIAID) [E]
(b) (6) Barasch, Kimberly (NIH/NIAID) [C] (b) (6) Billet,
Courtney (NIH/NIAID) [E] (b) (6)
Subject: Run of show - 2/13, 9-10am White House Roundtable on COVID-19

Dr. Fauci,

Please see below for information we have received from HHS thus far regarding tomorrow's briefing on coronavirus at the White House. Patty has submitted your information via the WAVES link for the event. We are checking with HHS ASL to make sure your clearance has been processed.

We will share any additional information as we receive it. Please let me know if you have any questions.

Thanks,
Sara

White House Congressional Roundtable on Coronavirus
Date: Thursday, February 13
Time: 9:00 – 10:00 a.m.
Location: Roosevelt Room

Run of show:

- Acting Chief of Staff Mulvaney will open the proceedings and briefly frame all that we are doing and why we have asked the Members to assemble (to gain their insight and to seek their wisdom).

- Anne Schuchat will give a brief overview of current status and material issues.
- Anthony Fauci will give a brief explanation of our understanding of the virus and development of countermeasures.
- Brig Gen. Paul Friedrichs of DoD will provide a brief status report on force protection.
- Acting Chief of Staff Mulvaney will open the floor for questions and moderate the proceedings - possible that White House legislative affairs will stand in here (Eric Ueland or Mike McKenna).

Expected participants:

Members (confirmed RSVPs thus far)

Senator James Risch
Leader McCarthy
Rep. Kay Granger
Rep. Greg Walden
Rep. Nita Lowey

Briefers

DHS – Alex Zemek
CDC—Dr. Anne Schuchat
NIAID—Dr. Tony Fauci
ASPR—Dr. Bob Kadlec
FDA—Dr. Steve Hahn
DHS - Ken Cuccinelli
NSC – Anthony Riggiero
NSC – Matt Pottinger
State – Stephen Biegun (tentative)
DOD – Brig Gen. Paul Friedrichs

From: [REDACTED] (b) (6)
Sent: Wed, 12 Feb 2020 11:02:30 -0500
To: John Lauerman
Subject: Re: Interview

I tried calling but the call would not go through

On Feb 12, 2020, at 6:15 AM, John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net> wrote:

Hi Dr. Fauci: I saw that you spoke about the lack of major drugmakers stepping up to make coronavirus vaccine, and my colleague James Paton is working on a story about that issue. James's story has to do with a biosecurity initiative related to these types of threats at GSK that was started in 2016 and quickly put on the back burner. I don't know whether you'd want to comment on the company or its activities itself, but would be helpful if you could talk about the importance of getting big drugmakers involved in helping to fill the need for new vaccines. I'm in Geneva right now at the WHO coronavirus science forum, but hope we can talk for a minute or two. Best way to reach me is via Whatsapp, where my number is [REDACTED] (b) (6). Please let me know if/when you're free. Thanks and regards, JL

From: John Lauerman (BLOOMBERG/ NEWSROOM:) At: 02/07/20 15:53:34
To: [REDACTED] (b) (6)
Subject: RE: Interview
Understood. Hope you get a chance to rest

From: afauci@niaid.nih.gov At: 02/07/20 15:51:39
To: John Lauerman (BLOOMBERG/ NEWSROOM:)
Subject: RE: Interview

Sorry John. I am totally tied up right now and besides, I am completely hoarse and can barely speak. Let us try some other time.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)

FAX: (301) 496-4409

E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: John Lauerman (BLOOMBERG/ NEWSROOM:)

<jlauerman@bloomberg.net>

Sent: Monday, February 3, 2020 8:18 AM

To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)

Subject: Interview

Hi Dr. Fauci: How are you? I'm writing to see whether we can talk again for a few minutes. We're working on a biggish piece about the larger bio-security issue worldwide and what the coronavirus outbreak tells us about it. What can we do about the weakest links in disease control in poorer nations in Africa, Asia and elsewhere? The WHO today brought up the importance of access to health care along with spending on public health, and clearly this is an issue in poor counties. Is it also important in infectious disease in the US and if so, is it adequately recognized? Companies and research centers have made huge strides in quick development of vaccines and drugs; what can take it to the next level? Is there anything that could be done to attract more companies to this field? What kind of new technologies can help us track new viruses in the community? I've been talking with people using handheld nanopore sequencers to track coronavirus and Ebola; what else is out there? Do we need to do a better job of tracking the movement of people and goods? Also glad to get any other observations. Please give me a call today or tomorrow morning at [REDACTED] (b) (6) [REDACTED] or let me know when and at what number to call you. Thanks and regards, look forward to hearing from you, JL

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel. +44 (0) 2035 251028 cell [REDACTED] (b) (6)
<http://www.bloomberg.com>
<http://www.bloomberg.com/prognosis>

From: (b) (6)
Sent: Wed, 12 Feb 2020 10:24:06 -0500
To: Daniel Lucey
Subject: Re: Update IDSA Science Speaks post today # 10: PPE mass production and POlyclonal/mAbs Rx PReP and PEP

Thanks dan

On Feb 12, 2020, at 9:34 AM, Daniel Lucey <(b) (6)>wrote:

Bob K., Tony and Bob (Redfield),

Given the news of health care personnel in Wuhan and Hubei being infected, and acute shortage of PPE for COVID-19, I posted these Q&A s on the ID Society America "Science Speaks" website as the 10th in a series of my updates since January 6th.

The final Question asks and answers that mass production of COVID-19 PPE should occur now.

Dan
Hong Kong Feb. 12, 2020

<https://sciencespeaksblog.org/2020/02/12/immune-survivors-of-covid-19-protective-antibody-for-treatment-and-prophylaxis/>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 12 Feb 2020 15:23:15 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: Re: Business Council - Invitation to speak at the February 20-21, 2020 meeting at the Ritz Carlton (22nd and M St. NW), Washington, D.C.
Attachments: image003.jpg, image004.jpg, image005.jpg

Okay. Go with it

On Feb 12, 2020, at 9:38 AM, Folkers, Greg (NIH/NIAID) [E]

(b) (6) wrote:

Will add

I would vote for: no slides –

I would send these three papers (all on director's page) – CoV, Ebola, Ending HIV

<image003.jpg>

Foreign Policy

<image004.jpg>

<image005.jpg>

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 12, 2020 9:11 AM
To: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] (b) (6)
Subject: FW: Business Council - Invitation to speak at the February 20-21, 2020 meeting at the Ritz Carlton (22nd and M St. NW), Washington, D.C.

Kim – pls add all to the folder thx

G – this needs to be added to matrix. IT was a “fireside chat” that we thought would not include slides but see below – they are ok with a few slides

Will need to discuss things to send and topics given the “theme”

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marlene Colucci <mcolucci@businesscouncil.com>
Sent: Tuesday, February 11, 2020 6:29 PM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Cc: Adrienne Ball <aball@businesscouncil.com>; Gillian Auger <gauger@businesscouncil.com>
Subject: Re: Business Council - Invitation to speak at the February 20-21, 2020 meeting at the Ritz Carlton (22nd and M St. NW), Washington, D.C.

Patty,

I wanted to check back with you and Dr. Fauci on a few things in advance of his fireside chat with David Rubenstein on Friday, February 21.

- Are there any articles that Dr. Fauci thinks would be useful to send out to our CEOs in advance of the discussion (it may be something related to the Coronavirus or something that looks at the future of health and what CEOs should be thinking about in the next decade?)

- The theme for our upcoming meeting is “The Next Decade - Major trends in technology, geopolitics, politics, economy and health”. I have attached a copy of our Draft CONFIDENTIAL and list of attendees for Dr. Fauci’s reference.
- During his discussion with David Rubenstein, are there any slides he would like to use for reference? We do not use a lot of these but thought there might be slides that would aid in his discussion? Just let us know.

Warmest regards,

Marlene

Marlene Colucci

EXECUTIVE
DIRECTOR



T: 202-298-7650
C: (b) (6)
F: 202-785-0296

On Feb 5, 2020, at 9:19 AM, Marlene Colucci
<mcolucci@businesscouncil.com> wrote:

Thank you Patty for checking. As soon as I can find out whether Dr. Collins will also be a part of the discussion I will work on setting up that call. Ive been pressing their office so fingers crossed!

Marlene

Marlene Colucci

EXECUTIVE
DIRECTOR



T: 202-298-7650
C: (b) (6)
F: 202-785-0296

On Feb 5, 2020, at 9:01 AM, Conrad, Patricia (NIH/NIAID) [E]
<[REDACTED] (b) (6)> wrote:

Good morning:

Dr. Fauci will not be able to attend the dinner the night before but wanted me to thank you for thinking of him.

Best,
-patty

From: Marlene Colucci <mcolucci@businesscouncil.com>
Sent: Friday, January 31, 2020 2:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6); David Rubenstein [REDACTED] (b) (6); MaryPat Decker [REDACTED] (b) (6)
Subject: Business Council - Invitation to speak at the February 20-21, 2020 meeting at the Ritz Carlton (22nd and M St. NW), Washington, D.C.

Dear Dr. Fauci,

On behalf of our co-chairs for the winter meeting of The Business Council, David Rubenstein of The Carlyle Group and Ginni Rometty of IBM, we would like to formally invite you to participate in our meeting on February 20-21, 2020 in Washington, D.C. The theme of the meeting is "The Next Decade." (See formal invitation attached as well as list of CEO members).

We would like for you to participate in a 50 minute fireside chat with David Rubenstein (and possibly Dr. Francis Collins) to discuss the current coronavirus as well as what we should expect in the next decade. We want to give our CEOs insights into what the next 10 years will bring in terms of detection, diagnosis and treatment of diseases. All conversations are strictly off the record and closed press. We will cover all lodging and transportation.

As you know, The Business Council is comprised of the chief executive officers of the largest global corporations, representing all segments of the economy. We expect at least 150 CEO members, spouses and speakers to be in attendance.

As a participant you and your spouse are also invited to join us for our special reception, dinner and speaker at the REACH (Kennedy Center) on Thursday, February 20 at 6:30pm. It is the best opportunity for you to meet our CEO members and spouses, speakers and other special guests in an informal atmosphere.

If you are interested and available, please let me know. We can also set up a very brief call with you to discuss any additional details and answer any questions you may have. We look forward to hearing from you and would be honored to have you participate with us again.

Warmest regards,

Marlene

Marlene Colucci

EXECUTIVE
DIRECTOR



T: 202-298-7650
C: (b) (6)
F: 202-785-0296

New Online Views **304,257** Citations **0** Altmetric **2109**

Viewpoint

ONLINE FIRST

January 23, 2020

Coronavirus Infections—More Than Just the Common Cold

Catherine I. Paules, MD¹, Hilary D. Marston, MD, MPH², Anthony S. Fauci, MD³

[Author Affiliations](#) | [Article Information](#)

JAMA. Published online January 23, 2020. doi:10.1001/jama.2020.0757

ARGUMENT

On the Front Lines of the Trump Administration's Ebola Response

The United States has mounted a wide ranging response to the latest deadly outbreak, as only it can.

BY ALEX M. AZAR, RICHARD J. ANDERSON, ANTHONY S. FAUCI | NOVEMBER 4, 2014, 1:05 PM



Ending the Human Immunodeficiency Virus Pandemic: Optimizing the Prevention and Treatment Toolkits

Robert W. Elvinger, Gregory K. Folkers, Anthony S. Fauci

Clinical Infectious Diseases, Volume 69, Issue 12, 15 December 2019, Pages 2212–2217,
<https://doi.org/10.1093/cid/ciz998>

Published: 24 October 2019 [Article history](#)

New Online

Views **304,257**

Citations **0**

Altmetric **2109**

Viewpoint

ONLINE FIRST

January 23, 2020

Coronavirus Infections—More Than Just the Common Cold

Catharine L. Paules, MD¹; Hilary D. Marston, MD, MPH, PhD²; Anthony S. Fauci, MD²

NIH-001935

[➤ Author Affiliations](#) | [Article Information](#)


JAMA. Published online January 23, 2020. doi:10.1001/jama.2020.0757

ARGUMENT

On the Front Lines of the Trump Administration's Ebola Response

The United States has mounted a wide-ranging response to the latest deadly outbreak, as only it can.

BY ALEX H. AZAR II, ROBERT R. REDFIELD, ANTHONY S. FAUCI | NOVEMBER 4, 2018, 1:55 PM



Ending the Human Immunodeficiency Virus Pandemic: Optimizing the Prevention and Treatment Toolkits

Robert W Eisinger, Gregory K Folkers, Anthony S Fauci 

Clinical Infectious Diseases, Volume 69, Issue 12, December 2019, Pages 2212–2217, <https://doi.org/10.1093/cid/ciz998>

Published: 24 October 2019 **Article history** ▼

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 12 Feb 2020 12:04:55 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: epiqar for Coronavirus assistance

Please handle. Thanks.

From: Daniel Goldberg <daniel@eng.us>
Sent: Tuesday, February 11, 2020 11:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>
Subject: epiqar for Coronavirus assistance

Dr. Fauci,

I wanted to reach out to see if **epiqar** (<https://epiqar.com/>) can help your efforts with the Coronavirus- we are the only system in the world built for remote surgical help & interactive emergency surgeon support over the web browser.

epiqar has created the most advanced surgical video collaboration technology, allowing surgeons to consult and train remotely on a low-cost and easy-to-use online surgical collaboration platform and Cloud-archiving system built for the operating room. With the outbreak of Coronavirus, this has become more vital as surgeon mobility and access to critical surgical spaces in need of more help are severely limited, and specialists will not risk entering spreading viral hot zones.

Patient care isn't just a concern with the virus itself, but with the host of medical issues facing patients that will no longer be treated by local specialists easily, and facing caregivers: surgeon involvement from around the world is needed urgently.

Although **epiqar** is an American company, our rollout in recent months has been in France, making selected French institutions the most prepared in the world for remote video care. We obviously weren't anticipating the Coronavirus and now we're dedicated to delivering our technology to where the world needs it asap.

epiqar's parent company **ENGAUGE** (<https://eng.us/>) is a state-of-the-art online healthcare company for surgeon training and has served clients such as **Johnson & Johnson, Intuitive Surgical**, and many other of the world largest & smallest medical device companies. **ENGAUGE** has helped surgeons all over the world have access to secure online training that has improved their understanding of the innovations in robotics and many of the latest surgical techniques and medical devices for best patient care.

I've linked a whitepaper below with details of the system's use. Please let me know if you would like to speak further and/or need anything additional.

Thanks,

Danny

www.epiqar.com

[epiqar | **whitepaper**](#)

Daniel Goldberg

CEO

ENGAUGE

www.eng.us

www.epiqar.com

The world's first low-cost telementoring, surgeon training and instant Cloud-archiving Platform

US 888.615.7874

EUROPE 44 2031399059

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 12 Feb 2020 00:16:12 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: AMA news interview request: What to tell your patients about COVID-19

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Sara Berg <Sara.Berg@ama-assn.org>
Sent: Tuesday, February 11, 2020 4:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: AMA news interview request: What to tell your patients about COVID-19

Dear Dr. Fauci,

My name is Sara Berg and I am a senior writer for the AMA. I am reaching out to you today because you have shared a lot of great information about COVID-19 with the JAMA network. I know you are very busy, but I was wondering if you would be available tomorrow or Thursday for a quick phone interview about what to tell patients who suspect they have COVID-19? This would be an AMA news article for physicians about what to tell patients. The CDC has a list of preventive steps:
<https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-prevent-spread.html>.

This would be what physicians should tell patients who suspect they have COVID-19. One tip might be "Call before you come in." Do you think this is something you would be available to participate in?

I look forward to hearing from you.

Thank you,



Sara Berg

Senior Communications Specialist

Sara.Berg@ama-assn.org

Office: (312) 464-4104



[AMA membership: Join or renew today!](#)

**MEMBERSHIP
MOVES
MEDICINE™**

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 12 Feb 2020 00:13:52 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: 2019 nCoV brief fyi (2+ pages)
Attachments: Brief 2019 nCoV host Se status.doc

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Michalann Harthill (b) (6)
Sent: Tuesday, February 11, 2020 3:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Morens, David (NIH/NIAID) [E] (b) (6)
Subject: 2019 nCoV brief fyi (2+ pages)

Dear Dr. Fauci,

Please find attached, FYI , my synopsis **Emergence of a novel coronavirus (2019-nCoV), Wuhan, Hubei Province, China: human host selenium-deficient status as a possible “driving” etiological determinant.** (2 1/4 pages, ~70 refs, no graphics)

Best regards,
Michal Harthill
GHI, Inc., Frederick, MD
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 12 Feb 2020 00:05:00 +0000
To: [REDACTED] (b) (6)
Subject: FW: take a look at figure 3 of the new nejm paper
Attachments: nejmoa2001316.pdf

See Greg/David comment below.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6) >
Sent: Tuesday, February 11, 2020 2:50 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: take a look at figure 3 of the new nejm paper

[REDACTED] (b) (5)

Thanks david

From: Folkers, Greg (NIH/NIAID) [E]
Sent: Tuesday, February 11, 2020 10:04 AM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: this is the nejm paper discussed this a.m.

That asf is opining on

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 23:58:00 +0000
To: NIAID OD AM
Subject: FW: Keynote Invitation: 3/20 CSIS Coronavirus Public Event

This could be good since it is local. Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stephen Morrison <SMorriso@csis.org>
Sent: Tuesday, February 11, 2020 1:20 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Anna Carroll <ACarroll@csis.org>; Samantha Stroman <SStroman@csis.org>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Keynote Invitation: 3/20 CSIS Coronavirus Public Event

Dear Dr. Fauci,

I hope this note finds you well. It is my pleasure to invite you to be the opening keynote speaker at a CSIS public event on coronavirus on **Friday, March 20, 1:30-3:30 pm at CSIS** (1616 Rhode Island Avenue NW). The event will focus on the science, economics, and politics of the coronavirus and will feature experts on Chinese and international politics and economics, as well as public health. We would ask you to speak approximately **1:30-2:00 pm**. Your keynote would be followed by a panel discussion and a closing address, and we invite you to stay for as much of the event as you are able. Please find the full draft agenda and speakers for the event below for your reference.

We would be honored to have you participate in this important and timely event. Thank you for your consideration, and please let us know if you would like to discuss further or if we can answer any questions. We look forward to hearing from you.

Best,
Steve

Draft Agenda:

1:30-2:00 pm – Opening Keynote

Dr. Anthony Fauci, NIAID

Introduced by Steve Morrison, CSIS Global Health Policy Center

2:00-2:50 pm – Panel Discussion

[The economics/business] Joyce Chang, JP Morgan (*confirmed*)

[The politics] Jude Blanchette, CSIS Freeman Chair in China Studies (*confirmed*)

[The foreign politics] Melanie Hart, Center for American Progress (*to be invited*), or Bonnie Glaser, CSIS China Power Project

[The public health] Steve Morrison, CSIS Global Health Policy Center (*confirmed*)

Moderator: Scott Kennedy, CSIS Trustee Chair in Chinese Business and Economics

2:50-3:30 pm – Newsmaker Speech

Matt Pottinger, NSC (*to be invited*)

Moderator and Follow-up Interview: Bonnie Glaser, CSIS China Power Project

J. Stephen Morrison

Senior Vice President & Director, Global Health Policy Center

Center for Strategic and International Studies (CSIS)

1616 Rhode Island Ave NW

Washington D.C. 20036

(202) 775-3276

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 23:45:51 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Pharmacist's/Prescriber's Letter Review Request - Coronavirus

Please take a look at this and respond for me.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jennifer Nieman <jnieman@pletter.com>
Sent: Tuesday, February 11, 2020 11:00 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Pharmacist's/Prescriber's Letter Review Request - Coronavirus

Dear Dr. Fauci,

In the March 2020 issues of *Pharmacist's Letter* and *Prescriber's Letter*, we plan to write about coronavirus.

Pharmacist's and *Prescriber's Letter* is an independent advisory service for pharmacists and physicians. We are not affiliated with any other group, organization, or company. We are 100% subscriber supported. Our focus is providing practical, unbiased advice to subscribers on issues related to drug therapy. Each month we turn to experts like you to help us pin down the most relevant and important information to share with our readers. Our newsletter is well known for being concise and accurate. You will notice the excerpt we are sending you is relatively short.

We would be most appreciative if you would take just a few moments to review what we have written for accuracy and content. Please share any comments or suggestions for changes you may have on the article.

In order to incorporate your comments into the final *Letter*, please let me hear from you by **Monday, Feb. 17th**. I can be reached by email jnieman@PLetter.com or phone (402) 660-4715.

I look forward to your reply.

INFECTION CONTROL

The ongoing outbreak of the novel coronavirus will raise questions about how to limit the spread of respiratory infections.

Managing this situation is similar to outbreaks of SARS and MERS...since coronaviruses are spread by respiratory secretions.

Put the risk in perspective to calm worried patients...since it doesn't come close to the risk of influenza.

For example, over 35 MILLION U.S. patients got the flu last season...with about 500,000 hospitalizations and 34,000 deaths.

Emphasize getting a flu vaccine each year.

And use this coronavirus outbreak as an opportunity to stress infection control...since there's no treatment or vaccine yet.

Reinforce proper hand hygiene. Educate that handwashing with soap and water is the best way to get rid of germs. Advise washing for 20 seconds...about the time it takes to sing the ABC song.

Or recommend using a hand sanitizer with at least 60% alcohol if handwashing isn't practical. Many products contain this much.

But tell patients to be wary of efficacy claims. For example, hand sanitizers are shown to kill enveloped viruses. Coronaviruses are enveloped viruses...but they aren't specifically studied.

Tell patients to avoid touching their eyes, nose, and mouth.

Clear up confusion about masks. Emphasize that masks are for SICK patients...to help keep their germs from getting into the air.

But discourage surgical masks for most patients without symptoms...there's no evidence they help. They're too loose to limit inhaling germs...and viruses can also get in through the eyes.

If patients ask about N95 respirators, tell them these require fitting and training before use. Save them for healthcare workers.

Caution that unnecessary mask use may contribute to shortages.

Continue to ask patients WITH respiratory symptoms to put a surgical mask on when they come to clinic.

And suggest that sick patients wear a mask at home if in close contact with infants, elderly, or immunocompromised patients.

Tell patients to discard masks when damp...and to use a fresh one at least daily.

Encourage patients to stay home when they're sick.

1. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>
2. <https://www.cdc.gov/coronavirus/2019-ncov/index.html>
3. <https://www.cdc.gov/flu/professionals/infectioncontrol/maskguidance.htm>
4. [https://www.who.int/publications-detail/advice-on-the-use-of-masks-the-community-during-home-care-and-in-health-care-settings-in-the-context-of-the-novel-coronavirus-\(2019-ncov\)-outbreak](https://www.who.int/publications-detail/advice-on-the-use-of-masks-the-community-during-home-care-and-in-health-care-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak)

Sincerely,

Jennifer A. Nieman, PharmD, BCPS

Associate Editor, [TRC Healthcare](#)

M: 402-660-4715 **E:** jnieman@pletter.com **W:** TRCHealthcare.com

Pharmacist's Letter | Prescriber's Letter | Natural Medicines | Pharmacy Technician's Letter | Pharmacy Technicians University

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 23:06:37 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: 【Dear Prof. Anthony Letter of interview from China Science Daily】

Can we please get someone to fashion answers for me to edit and send to her.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: 韩扬眉 <yghan@stimes.cn>
Sent: Monday, February 10, 2020 2:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: 【Dear Prof. Anthony Letter of interview from China Science Daily】

Dear Prof. Anthony,

I am yangmei Han, a journalist from CHINA SCIENCE DAILY.

China Science Daily is a newspaper in Chinese, published by The Chinese Academy of Sciences.

Recently, your article “Coronavirus Infections—More Than Just the Common Cold” mention about vaccines research in NIAID. We are interested and there are some questions and I want to get more informations.

1、What is the current research progress about vaccines in NIAID?

- 2、What are the factors restricting the development of vaccines ? and did you break through them?
- 3、What is the standard of vaccine that can be injected to patients? and according your forecasting, how will it work ?
- 4、Can this vaccines research play a role in the 2019-nCoV? Or as a treatment for a common infectious disease in the future?
- 5、Does vaccines have side effects ? how can we restrain it ?
- 6、If vaccines research success in a certain country, Will it be open to the world ? if it will, what conditions will need for open ?

if you could, we would like you reply as soon as possible

Thank you very much

I am looking forward to your reply!

Sincerely yours,
Yangmei Han (Miss)

--

韩扬眉

中国科学报社采访中心记者

邮箱：ymhan@stimes.cn;576942717@qq.com

电话：(b) (6)

地址：北京市海淀区中关村南一条乙中国科学报社

中国科学报社：由中国科学院、中国工程院、国家自然科学基金委员会和中国科学技术协会主办。
。普及科学知识、倡导科学方法、传播科学思想、弘扬科学精神。

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 20:54:02 +0000
To: Natalie Rahhal
Subject: RE: Interview re: coronavirus patient characteristics

If this is true, which it might not be, there is no clear explanation for why right now. There will likely be studies coming out that say that the relative proportion of male:female is closer to 50:50. Even one of the ones that you quoted was 54%

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Natalie Rahhal <Natalie.Rahhal@mailonline.com>
Sent: Tuesday, February 11, 2020 1:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Interview re: coronavirus patient characteristics

Hi Dr Fauci,

I'm sure you're extraordinarily busy right now, but I've seen several studies and reports that coronavirus seems to disproportionately strike men (making up 54-68% of cases, depending on which study you reference). I was wondering if you might have any comments to offer on why this might be?

Thank you,

Natalie A Rahhal
Acting US Health Editor

Daily **Mail**.com



Daily Mail Online | 51 Astor Place, 9th floor, New York NY 10003

Tel: +1 212 402 9086

Mobile: (b) (6)

Twitter: <https://twitter.com/natalier78?lang=en>

Email: Natalie.rahhal@mailonline.com

Disclaimer

This e-mail and any attached files are intended for the named addressee only. It contains information, which may be confidential and legally privileged and also protected by copyright. Unless you are the named addressee (or authorised to receive for the addressee) you may not copy or use it, or disclose it to anyone else. If you received it in error please notify the sender immediately and then delete it from your system. Associated Newspapers Ltd. Registered Office: Northcliffe House, 2 Derry St, Kensington, London, W8 5TT, Registered No 84121 England.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 20:10:45 +0000
To: Nabel, Gary /US
Subject: RE: WHO meeting

Gary:

Thanks for the note. [REDACTED] (b) (4)

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Nabel, Gary /US [REDACTED] (b) (6)
Sent: Tuesday, February 11, 2020 1:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: RE: WHO meeting

Not a problem. I just wanted you to know that I was willing to help.

[REDACTED] (b) (4)

Best
Gary

-----Original Message-----

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Sent: Monday, February 10, 2020 3:07 PM
To: Nabel, Gary /US <[REDACTED] (b) (6)>

Subject: [EXTERNAL] RE: WHO meeting

EXTERNAL : Real sender is [REDACTED] (b) (6)

I submitted your name to the group as one of my priority suggestions. I have no idea whom they will select.

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (301) 496-2263

FAX: (301) 496-4409

E-mail: afauci@niaid.nih.gov

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Nabel, Gary /US [REDACTED] (b) (6)

Sent: Monday, February 10, 2020 2:17 PM

To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)

Subject: WHO meeting

Hi Tony

Thanks for taking the time to talk and help with the HIV trispesific work last week. I appreciate your efforts.

While I was there, you mentioned a WHO Coronavirus meeting you thought I should join. I'm happy to attend but have not yet received an invite. Sometimes WHO excludes companies from such meetings, which is unfortunate and to their detriment. In any case, please let me know if I can help in any way.

Best regards

Gary

Sent from my iPhone

From: (b) (6)
Sent: Tue, 11 Feb 2020 11:22:43 -0500
To: Martin Blaser
Cc: Conrad, Patricia (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIAID) [E];Lane, Cliff (NIH/NIAID) [E]
Subject: Re: SARS 2003, Influenza 2009 and the present

Marty:

Thanks for the note. Indeed, immune sera is foremost on our mind as are mAbs. Hope that all is well with you.

Best,
Tony

On Feb 11, 2020, at 9:55 AM, Martin Blaser
(b) (6) wrote:

Dear Tony,

I dont mean to bother you, but I have a suggestion, in case you have not considered it.

China will have hundreds of thousands of Coronavirus survivors. Their convalescent (immune) serum is valuable. China should try to collect it and give it as a good-will gesture to people around the world.

For moderately to seriously ill people, Immune serum should save many lives.

If cases start to come here, we also should collect serum from survivors, but hopefully we will be very late in the pandemic, and it is not needed because of all of the others things you are doing.

Thank you for everything you and NIAID are doing!

Best wishes, Marty

(Just as in SARS, the Ro for nCo-2019 is higher in hospitals than in the community, but it still is too high in the community).

Martin J. Blaser, M.D.
Henry Rutgers Chair of the Human Microbiome
Professor of Medicine and Microbiology – RWJMS
Director, Center for Advanced Biotechnology and Medicine
Rutgers University
679 Hoes Lane West, Room 106A
Piscataway, NJ 08854

Office Phone: (b) (6)
Fax: 732-235-5318
Email: (b) (6)

<https://cabm.rutgers.edu>

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Sunday, January 26, 2020 7:16 PM
To: Martin Blaser (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: RE: SARS 2003, Influenza 2009 and the present

Marty:

Many thanks. This is very helpful.

Best regards,

Tony

From: Martin Blaser (b) (6)
Sent: Saturday, January 25, 2020 9:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: SARS 2003, Influenza 2009 and the present

Webb G, Blaser MJ, Zhu H, Ardal S, Wu J. Critical role of nosocomial transmission in the Toronto SARS outbreak. *Mathematical Biosciences and Engineering* 2004; 1: 1-13. [PMID: 20369956] [Paper of the year, 2004]

Webb GF, Hsieh Y-H, Wu J, Blaser MJ. Pre-symptomatic influenza transmission, surveillance, and school closings: implications for novel influenza A (H1N1). *Mathematical Modelling of Natural Phenomena* 2010; 5:191-205.

Dear Tony,

Thanks for your JAMA piece on 2019-nCoV. Perhaps I can help in a small way:

In 2003, with SARS, the R_0 was initially considered to be over 2, but in fact that was the conflation of the nosocomial and community rates. In the 2004 paper, we showed that nosocomial rate was much higher, and that the R_0 in the community was between 1 and 2. A lower R_0 in the community accounts for why moderate public health actions could move it toward extinction--and why it propagated in Beijing, but not Shanghai, in Toronto

but not in Vancouver--the Ro in North America became less than one pretty quickly.

To me, one important aspect is the control of respiratory transmission in the hospital, avoiding extensive nebulization/aerosolization, or doing so in negative pressure rooms, as for TB isolation.

(Treating patients with robots is a good idea!)

In the community, standard public health quarantine, contact tracing should be sufficient for starters.

Although hundreds of cases are reported in China, the actual number of infections is likely much higher. The 41 deaths are the tip of the iceberg of not 800 infections (5% fatality rate), but maybe 8,000 infections (0.5%). Although that rate is much better, if the mutating virus becomes very contagious—then the impact could be similar to 1918 flu. That's why containment is so important.—and although draconian, the Chinese government is doing the right thing (as far as we know).

When a new pathogen arrives, children often have mild disease but they are important vectors for transmission in the community, reaching many households. The second paper is the importance of closing schools to minimize transmission—This was for flu with a short (pre-symptomatic) incubation, but may be even more relevant for 2019-nCoV. It is much too early to even think of this in the USA, but it may come to this--and sooner will be better than later, when that time point comes.

Happy to help, any way that I can. Thank you for all you and NIAID are doing!!!

Best wishes , Marty

Martin J. Blaser, M.D.
Henry Rutgers Chair of the Human Microbiome
Professor of Medicine and Microbiology – RWJMS
Director, Center for Advanced Biotechnology and Medicine
Rutgers University
679 Hoes Lane West, Room 106A
Piscataway, NJ 08854

Office Phone: [REDACTED] (b) (6)

Fax: 732-235-5318

Email: [REDACTED] (b) (6)

<https://cabm.rutgers.edu>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 13:22:53 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Interview / Coronavirus vaccine - Pazienti.it

Have Jen Routh or someone prepare brief responses that I can check. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alessandra Lucivero <alessandra.lucivero@pazienti.it>
Sent: Tuesday, February 11, 2020 5:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Camilla Mantegazza <camilla.mantegazza@pazienti.it>; Irene Bocca <irene.bocca@pazienti.it>
Subject: Interview / Coronavirus vaccine - Pazienti.it

Good morning prof. Fauci,
my name is **Alessandra Lucivero** and I'm the **Editorial Manager of [Pazienti.it](https://www.pazienti.it)**, an Italian health website, followed by over 3 million users every month.

We would like to ask you some **questions related to the Coronavirus vaccine**.
We will publish the interview in Italian on our blog here: <https://www.pazienti.it/news-di-salute>.

The questions are:

- *Coronavirus vaccine: when will it be available? What are the difficulties?*
- *Could the Coronavirus mutate, if a vaccine cannot be found in time?*
- *Will the vaccine be the solution against Coronavirus?*

I hope you can be kind enough to answer my questions.
I look forward to hearing from you.

Thank you very much for your time.

Alessandra Lucivero

--
Alessandra Lucivero
Responsabile editoriale
alessandra.lucivero@pazienti.it

pazienti.it

Il portale della salute dove farsi vedere da uno bravo.



Questo messaggio e i suoi allegati sono indirizzati esclusivamente alle persone indicate. La diffusione, la modifica, la riproduzione di queste informazioni sono vietate. Qualora abbiate ricevuto questo documento per errore, vi preghiamo di comunicarlo al mittente e di provvedere alla sua eliminazione. Vi informiamo inoltre che questo indirizzo di posta è utilizzato solo a scopo professionale: non si garantisce che la corrispondenza verso questa casella venga letta dal solo destinatario poiché, in determinate circostanze, l'accesso può avvenire anche da parte di terzi appartenenti alla Società. Pertanto si consiglia di non inviare messaggi di natura personale. Grazie.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 13:14:45 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Coronavirus Auto Termination
Attachments: Retrovirus Auto Termination.PDF

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Pali Nazir (b) (6) >
Sent: Tuesday, February 11, 2020 4:32 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) Chun, Tae-Wook (NIH/NIAID) [E]
(b) (6); Connors, Mark (NIH/NIAID) [E] (b) (6); Lane, Cliff
(NIH/NIAID) [E] (b) (6); Lusso, Paolo (NIH/NIAID) [E] (b) (6); Sereti, Irini
(NIH/NIAID) [E] (b) (6)
Subject: Coronavirus Auto Termination

Dear Mrs. / Sir,

We have a solution to the new recent global problem Coronavirus (2019-nCoV).

Best Regards,
Dr. Pali Nazir

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 13:12:28 +0000
To: Casseti, Cristina (NIH/NIAID) [E]
Subject: FW: coronaviruses

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: (b) (6)
Sent: Tuesday, February 11, 2020 8:01 AM
To: (b) (6)
Holbrook, Michael
(NIH/NIAID) [C] <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: coronaviruses

Hello,

Working as an occupational physician in France, I would like to draw your attention to the antiviral activity of proton pump inhibitors, including for the Gibbon Ape Leukemia virus, a virus which does not require acidification of endosomes for entry into cells, as is the case with coronaviruses.

Indeed, in 2015 Long et al. (1) found that «...The commonly used proton pump inhibitors, Omeprazole and Esomeprazole were also able to inhibit entry of all PVs tested but at higher drug concentrations than may be achieved in vivo...».

Using omeprazole and esomeprazole magnesium hydrate, prepared in sterile DMSO (Sigma), they concluded that «... OM and ESOM appeared to decrease fluorescence, and therefore increase endosomal pH, only at a concentration of 200µM, higher than that required to inhibit PV entry. Moreover cellular toxicity was observed at this concentration after 24 hours...».

In 2016, Dowall et al. (2) found : «...Whereas omeprazole and esomeprazole demonstrated in vitro activity against EBOV, the results were in line with a previous report using pseudotyped viruses where the values of drug concentration causing 50% inhibition (IC50) were in the region of 50 µM [10]. This suggested that doses required for potent inhibition would be difficult to achieve without concomitant and significant toxicity (the licenced dosing for 40 mg esomeprazole, 20 mg esomeprazole and 20 mg omeprazole generates median maximum plasma concentrations of 1.59–9.61 µM, 0.51–4.78 µM and 0.15–3.51 µM, respectively...».

However, omeprazole is marketed in a non-ionized form and must be ionized (in acidic environment) to be

transformed into an active molecule(3). It is the ionized form which establishes covalent bonds with the SH group of the cysteine of the a subunit of the proton pump.

The solution used in 2015 by Jason Long et al. was, as in 2016 by Dowall et al., DMSO(Dimethyl Sulfoxide).

DMSO is a polar and aprotic organic solvent with dissociation constant $pK_a = 35.1$ This is probably an explanation for the surprising findings from these studies regarding proton pump inhibitors: Inhibition of viruses at 100 μM (at 50 μM esomeprazole for 4 of the 5 viruses tested) and increase in endosomal pH only at a concentration of 200 μM .

This is a situation which, from my point of view, does not reflect the human tissue situation, because in this situation omeprazole can be ionized in the intracellular space but also already in the extracellular space.

Besides, that's probably its advantage: to be ionized and activated where there is an acidic environment.

Without taking into account the tissue situation and the need that omeprazole must be ionized to be transformed into an active molecule, it would not be possible to explain the following publications, since it would be impossible to obtain tissue concentrations required:

- « Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy » (4)
- « Anti-Rhinovirus activity of lansoprazole, which was probably due to an endosomal anti-acidic mechanism » (5)
- « The use of omeprazole family compounds was associated with a lower probability of influenza-like illness » (6)
- « PPIs exert an antiviral function by effectively inhibiting virus-specific serine proteases » (7)
- « Proton pump inhibitors for chronic obstructive pulmonary disease » (8)
- « The ngH,K-ATPase shares approximately 65% sequence homology with the gH,K-ATPase » (9)
- « Omeprazole blocked another P-type ATPase, ATP7A (Menkes protein) in human epidermal mélanocytes » (10)
- « pH-dependent antitumor activity of proton pump inhibitors » (11)
- « V-ATPase as a candidate target molecule or biomarker for cancer treatment and provide a potential role for omeprazole as a chemosensitizer in clear cell carcinoma of the ovary » (12)
- « Proton pump inhibitors such as omeprazole, used clinically to suppress gastric acidity in gastritis, are activated by acidic conditions and tend to decrease intracellular pH and increase the extracellular pH via inhibition of V-ATPases in a covalent interaction » (13)
- « proton pump inhibitors have been shown to be highly effective at inhibiting V-ATPases in vitro » (14)

Specifically at the pulmonary level, we observe concerning proton pump inhibitors:

- « ...Since ATP12A shares approximately 65% identity with the gastric H⁺/K⁺-ATPase (ATP4A), we investigated the potential of using clinically approved ATP4A proton pump inhibitors (PPIs) for their ability to restore ASL pH in CF hAECs. We show that, despite not expressing ATP4A transcripts, acute exposure to the PPI esomeprazole, produced changes in intracellular pH that were consistent with the inhibition of H⁺ secretion, but this response was independent of ATP12A. More importantly, chronic exposure of CF hAECs to esomeprazole alkalinized the ASL without disrupting the epithelial barrier integrity, but this increase in ASL pH was consistent with a decrease in mRNA expression of ATP12A. We conclude that PPIs may offer a new approach to restore ASL pH in CF airways, which is independent of CFTR.... » (15)

· « ...On the other hand, even though the gastric H⁺/K⁺-ATPase was not expressed in airway epithelial cells, exposure to esomeprazole acidified the cytosol and increased ASL pH of primary CF hAECs. We show that esomeprazole had a dual mechanism of action: acutely, it induced intracellular acidification in an ATP12A-independent manner but, chronic exposure, which importantly did not have any deleterious effect on epithelial integrity, was linked to decreased ATP12A mRNA levels. These results open up the possibility of repurposing PPIs as a new therapeutic approach for treating CF lung disease... » (15)

· « ...we found that the mRNA of ATP12A, the non-gastric H⁺/K⁺-ATPase, shares 70% identity with the gastric H⁺/K⁺-ATPase, ATP4A mRNA, which translates to around 65% identity in the protein products... » (15)

· « Proton pump inhibitor therapy predisposes to increased risk of developing pneumonia » (16)

· « Na⁺/H⁺ Exchangers Are Required for the Development and Function of Vertebrate Mucociliary Epithelia » (17)

· « ATP4a is required for development and function of the *Xenopus* mucociliary epidermis - a potential model to study proton pump inhibitor-associated pneumonia » (18)

Regarding coronaviruses and Golgi complex:

· « ...Coronaviruses (CoVs) acquire their envelopes from the endoplasmic reticulum–Golgi intermediate compartment (...), also called the cis-Golgi network (...). The three main envelope proteins (S, M and E) are synthesized in the ER and move to the ERGIC/Golgi region where they orchestrate assembly of virus by interacting with the viral nucleocapsid (...). Once virions have budded into the lumen of the ERGIC, the ~120 nm particles must move through the host secretory pathway to be released from infected cells. Coronaviruses are believed to follow the constitutive secretory pathway for exocytosis, although only a few studies have addressed the release of virions. During infection, a progressive disruption of Golgi structure is observed, with swollen unstacked cisternae late in infection... »

« ...Weak bases (which disrupt acidification), v-ATPase inhibitors, and expression of a pH activated proton channel all block a number of membrane trafficking steps (...) One mechanism for how luminal pH can affect vesicular trafficking involves a subunit of the membrane sector of the v-ATPase, which has been shown to act as a pH sensor in endosomes. This subunit undergoes a conformational change as the luminal pH drops, which recruits cytoplasmic machinery leading to subsequent vesicle formation... » (19)

· « ...Pharmacological and other manipulations of the pH gradient that result in neutralization of the lumen have all been shown to cause slow trafficking of cargo through the Golgi complex as well as alteration in Golgi morphology... »

« ...Similar to M2, the infectious bronchitis virus (IBV) coronavirus E protein elicits multiple secretory pathway disruption phenotypes when overexpressed in mammalian cells... » (20)

· « ...The envelope protein (E) of coronaviruses plays an important role in virus assembly (...) Using coronavirus infectious clones, it was shown that the transmissible gastroenteritis virus E protein is essential for virus production, and murine hepatitis virus lacking E protein is viable but extremely debilitated... »

« ...The exact mechanism of coronavirus release after budding into the endoplasmic reticulum–Golgi intermediate compartment is not known. Large vacuoles containing budded virions are observed in infected cells, presumably en route to the plasma membrane where fusion of the vacuole results in release of virions... » (21, 22)

· « ...It might be worth investigating whether ion-channel inhibitors, such as amantadine, or proton pump inhibitors specifically are able to inhibit this increase in Golgi pH. For now, though, it still remains to be seen whether CoV release is mediated by viroporin ion channel activity or through PPIs with host proteins of the secretory pathway... » (23)

· « V-ATPases are also important for transportation of newly synthesized acid hydrolases from Golgi to lysosomes » (24)

· «...cardiotonic steroids ouabain and bufalin, which are known not to affect the transport function of Na⁺,K⁺-ATPase, inhibited infection of cells with MHV, FIPV, Middle East respiratory syndrome (MERS)-CoV, and VSV, but not IAV, when the compounds were present during virus inoculation. Cardiotonic steroids were shown to inhibit entry of MHV at an early stage, resulting in accumulation of virions close to the cell surface and, as a consequence, in reduced fusion. In agreement with an early block in infection, the inhibition of VSV by CTSs could be bypassed by low-pH shock. Viral RNA replication was not affected when these compounds were added after virus entry. The antiviral effect of ouabain could be relieved by the addition of different Src kinase inhibitors, indicating that Src signaling mediated via ATP1A1 plays a crucial role in the inhibition of CoV and VSV infections...» (25)

In conclusion, in order to verify the possible efficacy of omeprazole and esomeprazole in the control of infection by coronaviruses :

· The equivalent of the maximum serum concentration that can be obtained in the human body should be used and tested in active (ionized) form in vitro.

Unlike an in vitro test, the human body is an open system, a dissipative system. However, local concentrations of the ionized form should not exceed serum concentrations of the inactive non-ionized form in the absence of active transport.

But the transformation from the non-ionized form to the ionized form could continue until the saturation of the reactions at the cellular level or until the depletion of the transformation capacity from the inactive form to an active form, linked to a change in acidity or the depletion of the inactive form.

· As omeprazole can modify or even inhibit the action of the M2 protein of the influenza virus at the cellular level (26), based on a computer simulation test, it would be desirable to check the interaction capabilities of omeprazole with protein E of the coronavirus. Protein E is likely to resemble the protein M2 in its mode of action.

· In the absence of a treatment recognized as effective in the context of a coronavirus infection and in the absence of data clearly demonstrating the ineffectiveness of omeprazole, personally, I would be tempted to take omeprazole after being in contact (at a distance of less than 2 to 3 meters) with people at risk of contamination or if I had the first symptoms, hoping for the inhibitory activity of omeprazole on P-type ATPases (27, 28) in the context of coronavirus exocytosis, in analogy to the action "off target on the endosomal vATPase" during endocytosis processes.

This step, if effective, will not prevent infection, but could lessen its importance, slow the process down and give the immune system a complementary option to defend itself...

· Personal experience, using omeprazole in the context of seasonal respiratory viral infections since 2007, reminds me of the indication to divide the daily dose into two daily doses (omeprazole 10mg morning and evening is usually already effective for seasonal respiratory viral infections). According to the evolution and the importance of inflammatory state I associate an antihistamine, eg cetirizine.

In the context of the coronavirus, I would be tempted

· share the maximum permissible daily dose of omeprazole in 3 divided doses after being in contact with people at risk of contamination at a distance of less than 2 to 3 meters

· divide the daily dose of omeprazole into two daily doses in case of minor symptoms

· take the daily dose of omeprazole in a single dose if the symptoms worsen with repercussions on the general condition

· to resume the daily dose of omeprazole in two daily doses when the symptoms of severity diminish.

The effectiveness of esomeprazole may be greater than omeprazole.

Taking into account the aforementioned publications, it should not be forgotten that omeprazole will reduce secretions at the respiratory level. A positive effect on respiratory secretions during acute viral respiratory diseases which can become negative (by modifying the pH, the ciliary mobility and the volume of secretions) during prolonged use, thus promoting the risk of bacterial pneumonia (29).

The advantages and disadvantages may vary depending on the user phenotype of omeprazole with regard to cytochrome P 450 (30).

Best regards

Johannes Hambura

1. Long J, Wright E, Molesti E, Temperton N, Barclay W. Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. *F1000Res*. 2015;4:30. Published 2015 Jan 29. doi:10.12688/f1000research.6085.2
2. Dowall SD, Bewley K, Watson RJ, et al. Antiviral Screening of Multiple Compounds against Ebola Virus. *Viruses*. 2016;8(11):277. Published 2016 Oct 27. doi:10.3390/v8110277
3. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. *J Neurogastroenterol Motil*. 2013;19(1):25–35. doi:10.5056/jnm.2013.19.1.25
4. Spugnini EP, Citro G, Fais S. Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. *J Exp Clin Cancer Res*. 2010;29(1):44. Published 2010 May 8. doi:10.1186/1756-9966-29-44
5. Sasaki T, Yamaya M, Yasuda H, Inoue D, Yamada M, Kubo H, Nishimura H, Sasaki H. The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. *Eur J Pharmacol*. 2005;14:201–210. doi: 10.1016/j.ejphar.2004.12.042.
6. Gasparini R, Lai PL, Casabona F, et al. Do the omeprazole family compounds exert a protective effect against influenza-like illness?. *BMC Infect Dis*. 2014;14:297. Published 2014 Jun 2. doi:10.1186/1471-2334-14-297
7. Moormann AEBDP, Flynn DL, Hui LI, Villamil CI, Inventor method of using (H+/K+)ATPase inhibitors as antiviral agents. United States 1999 Jun. 14, 2005.
8. Kikuchi S, Naoki Y, Tajiri T, Watanabe N. Proton pump inhibitors for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2018;2018(8):CD013113. Published 2018 Aug 30. doi:10.1002/14651858.CD013113
9. Modyanov N, Pestov N, Adams G, Crambert G, Tillekeratne M, Zhao H, Korneenko T, Shakhparonov M, Geering K. Nongastric H,K-ATPase: structure and functional properties. *Ann N Y Acad Sci*. 2003 Apr; 986():183-7.
10. Matsui MS, Petris MJ, Niki Y, Karaman-Jurukovska N, Muizzuddin N, Ichihashi M, Yarosh DB. Omeprazole, a gastric proton pump inhibitor, inhibits melanogenesis by blocking ATP7A trafficking. *J Invest Dermatol*. 2015 Mar; 135(3):834-841.
11. De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M, Mina PD, Santinami M, Rodolfo M, Podo F, Rivoltini L, Fais S. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. *Int J Cancer*. 2009.
12. Lee YY, Jeon HK, Hong JE, et al. Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma. *Oncotarget*. 2015;6(33):35040–35050. doi:10.18632/oncotarget.5319
13. Larsson H, Mattson H, Sundell G, Carlsson E. Animal pharmacodynamics of omeprazole. A survey of its

pharmacological properties in vivo. *Scand J Gastroenterol Suppl.* 1985;108:23–35.

14. Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, Federici C, Iessi E, Parmiani G, Arancia G, Belardelli F, Fais S. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. *J Natl Cancer Inst.* 2004;96:1702–1713.
15. Delpiano L, Thomas JJ, Yates AR, Rice SJ, Gray MA, Saint-Criq V. Esomeprazole Increases Airway Surface Liquid pH in Primary Cystic Fibrosis Epithelial Cells. *Front Pharmacol.* 2018;9:1462. Published 2018 Dec 11. doi:10.3389/fphar.2018.01462
16. de Jager CP, Wever PC, Gemen EF, van Oijen MG, van Gageldonk-Lafeber AB, Siersema PD, Kusters GC, Laheij RJ. Proton pump inhibitor therapy predisposes to community-acquired *Streptococcus pneumoniae* pneumonia. *Aliment Pharmacol Ther.* 2012 Nov;36(10):941-9. doi: 10.1111/apt.12069. Epub 2012 Oct 3.
17. Sun DI, Tasca A, Haas M, et al. Na⁺/H⁺ Exchangers Are Required for the Development and Function of Vertebrate Mucociliary Epithelia. *Cells Tissues Organs.* 2018;205(5-6):279–292. doi:10.1159/000492973
18. Walentek P, Beyer T, Hagenlocher C, et al. ATP4a is required for development and function of the *Xenopus* mucociliary epidermis - a potential model to study proton pump inhibitor-associated pneumonia. *Dev Biol.* 2015;408(2):292–304. doi:10.1016/j.ydbio.2015.03.013
19. Machamer CE. Accommodation of large cargo within Golgi cisternae. *Histochem Cell Biol.* 2013;140(3):261–269. doi:10.1007/s00418-013-1120-y
20. Jason W. Westerbeck, Carolyn E. Machamer. The Infectious Bronchitis Coronavirus Envelope Protein Alters Golgi pH To Protect the Spike Protein and Promote the Release of Infectious Virus. *Journal of Virology* May 2019, 93 (11) e00015-19; DOI: 10.1128/JVI.00015-19
21. Machamer CE1, Youn S. The transmembrane domain of the infectious bronchitis virus E protein is required for efficient virus release. Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA. PMID: 17037529 DOI: 10.1007/978-0-387-33012-9_33
22. Tooze, J., Tooze, S. A., and Fuller, S. D., 1987, Sorting of progeny coronavirus from condensed secretory proteins at the exit from the trans-Golgi network of AtT20 cells, *J. Cell Biol.* 105:1215.
23. Schoeman, D., Fielding, B.C. Coronavirus envelope protein: current knowledge. *Virology* 16, 69 (2019), <https://doi.org/10.1186/s12985-019-1182-0>
24. Pamarthy S, Kulshrestha A, Katara GK, Beaman KD. The curious case of vacuolar ATPase: regulation of signaling pathways. *Mol Cancer.* 2018;17(1):41. Published 2018 Feb 15. doi:10.1186/s12943-018-0811-3
25. Burkard C, Verheije MH, Haagmans BL, van Kuppeveld FJ, Rottier PJM, Bosch B-J, de Haan CAM. 2015. ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells. *J Virol* 89:4434–4448. doi:10.1128/JVI.03274-14
26. Bozdaganyan M, Orekhov Ph, Bragazzi N, Panatto D, Amicizia D, Pechkova E, Nicolini C, Gasparini R. Docking and Molecular Dynamics (MD) Simulations in Potential Drugs Discovery: An Application to Influenza Virus M2 Protein. *American Journal of Biochemistry and Biotechnology* 2014/11/08. 10.3844/ajbbbsp.2014.180.188
27. Lisa A. Dunbar and Michael J. Caplan. Ion Pumps in Polarized Cells: Sorting and Regulation of the Na⁺,K⁺- and H⁺,K⁺-ATPases. *J. Biol. Chem.* 2001 276: 29617-. doi:10.1074/jbc.R100023200
28. Amarelle L, Lecuona E. The Antiviral Effects of Na,K-ATPase Inhibition: A Minireview. *Int J Mol Sci.* 2018;19(8):2154. Published 2018 Jul 24. doi:10.3390/ijms19082154
29. Yu LY, Sun LN, Zhang XH, et al. A Review of the Novel Application and Potential Adverse Effects of Proton

Pump Inhibitors. *Adv Ther.* 2017;34(5):1070–1086. doi:10.1007/s12325-017-0532-9

30. El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. *Expert Opin Drug Metab Toxicol.* 2018;14(4):447–460. doi:10.1080/17425255.2018.1461835

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 12:52:45 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: WTOP Request

OK by me. Please set it up.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Tuesday, February 11, 2020 7:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Fwd: WTOP Request

1040 before you depart for aspen event?

Sent from my iPhone

Begin forwarded message:

From: "Chesson, Joslyn" <jchesson@wtop.com>
Date: February 11, 2020 at 7:16:26 AM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>
Subject: WTOP Request

Good morning,

Hoping Dr. Fauci has some availability this late morning and early afternoon to discuss the coronavirus and the quarantining on cruise ships.

We have 10:40a, 11:10a, and 12:10pm all open.

Let me know if any of those times work for him!

Thanks,

Joslyn Chesson
Editor
WTOP News
(202) 895-5060

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 12:20:02 +0000
To: Lisa Monaco
Subject: RE: The Coronavirus Shows Why the U.S. Must Make Pandemic Disease a National Security Priority - Lawfare

Lisa:

Thanks for the note and for sending this. Very nice piece! I hope that all is well with you. I miss very much our interactions.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Lisa Monaco <(b) (6)>
Sent: Monday, February 10, 2020 8:09 PM
To: Lisa Monaco (b) (6)
Subject: The Coronavirus Shows Why the U.S. Must Make Pandemic Disease a National Security Priority - Lawfare

In case you missed this, my latest on the coronavirus.

<https://www.lawfareblog.com/coronavirus-shows-why-us-must-make-pandemic-disease-national-security-priority>

Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 22:44:53 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject: RE: for review: responses for Washington Times
Attachments: responses to Washington Times 2.10.2020 AL - with Fauci tracked changes.docx

See my tracked changes in attached document. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Sent: Monday, February 10, 2020 4:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Billet, Courtney (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6); Lerner, Andrea (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Subject: for review: responses for Washington Times

Dr. Fauci –

The reporter Shen Wu Tan from the Washington Times reached out to us this morning with some questions about 2019-nCoV. I drafted proposed responses to these questions with input from Andrea. Please see attached. Please let me know if you have edits. I will send the final responses back to the reporter, and I will note they are attributed to you.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations

National Institute of Allergy and Infectious Diseases (NIAID)

NIH/HHS

31 Center Drive Room 7A17C

Bethesda, MD 20892

Direct: ([REDACTED]) (b) (6)

[REDACTED] (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 20:22:28 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Subject: FW: Wpost: Q&A with Anthony Fauci: Are we past the point of containment for coronavirus?

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Monday, February 10, 2020 2:37 PM
Subject: Wpost: Q&A with Anthony Fauci: Are we past the point of containment for coronavirus?

[Opinions](#)

Q&A with Anthony Fauci: Are we past the point of containment for coronavirus?



A man wears a protective mask while walking in Wuhan, China, on Feb. 10. (Stringer/AFP/Getty Images)



By

[Robert Gebelhoff](#)

Assistant editor and Opinions contributor

Feb. 10, 2020 at 2:22 p.m. EST

The latest strain of coronavirus continues to rage across China. Its death toll has surpassed 900, [eclipsing the body count](#) from China's SARS outbreak in 2002 and 2003.

To get a better sense of the disease and the U.S. government's response to it, we spoke to Anthony S. Fauci, immunologist and director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. Below is a transcript of an interview with Fauci, edited for clarity and brevity.

Robert Gebelhoff: Right off the bat, what makes this virus different?

Anthony Fauci: Well, we have to be concerned whenever there's a virus that has — and I'm going to use a big word here — pathogenic potential. ... [The coronavirus] is brand-new, and there's no real underlying experience with it, so the general population is naive with regard to protection. And it has serious potential, because it's already spreading rapidly. It's the unknown aspect of something that already tells you it's a serious problem. We don't know where it's going.

Gebelhoff: Are we past the point of containment for this coronavirus?

Fauci: No, we're not. The short answer is we're not past the point of containment. But it really does have the potential to turn into a global pandemic. What we have now is a very serious epidemic in China. ... [But outside of China,] there is very little — but some — transmission from person to person. Once you get multiple countries that have sustained transmission from person to person, then it's beyond the situation where you can contain it. You can only mitigate it. In the United States, we are clearly in the containment phase. ... And what we've done is we've identified. We've isolated. And we've done contact-tracing [identifying who might have come in contact with an infected person]. That seems to be successful. But once it starts spreading all over the world ... then it's almost inevitable that it's going to start spreading here.

Gebelhoff: The Post [reported](#) last week that China withheld information from the public, including silencing medical professionals, and that this made the spread of the virus worse. How does the United States work with a government that we can't even trust to tell the truth to its people?

Fauci: That is an issue. And it's the reason why I have been saying that we need some of our people — CDC, NIH people — there on the ground, both helping and seeing with their own eyes exactly the extent of this. We want to be part of a [World Health Organization] convening group that goes there. But thus far, we've not been able to make that a reality.

Gebelhoff: And why's that?

Fauci: I don't know. We have asked. We have colleagues — scientific colleagues — in China that we've dealt with for years if not decades. Many of them have trained in the United States. And we know them as friends and as colleagues. They are the ones that are not holding back. ... But they're not the ones that make the official proclamations of what comes out. The solution to the problem in the question you're posing is that we really do want people there, so that we can not only help them but also provide some expertise that might supplement or complement their own expertise.

Gebelhoff: What does the United States do if [the coronavirus] does become a pandemic in the developing world?

Fauci: Well obviously we will try to help them to contain as best as possible. ... Right now, by definition, it is not truly a global pandemic. It is a very serious outbreak and epidemic in China, but the amount of sustained transmission outside of China is still minimal. ... But there are some countries where it is going to be very difficult to stop the evolution into sustained transmission. Obviously the [World Health Organization] and the global security network that we put up over the years will try to help those countries, but there's no guarantee that we'll be successful.

Gebelhoff: On that point, the head of the WHO [has criticized](#) travel bans and restrictions around the world as not helpful to stopping the outbreak. He said it was potentially "increasing fear and stigma." What

Fauci: Everyone agrees that travel bans and restrictions are almost never successful in completely stopping something is that invariably going to turn into a pandemic. ... What we are trying to do is to pause temporarily and give China enough time to put the lid on [this virus] to prevent it from becoming global and to give us a little more time to prepare. There's no indication or imagination that if this becomes a global pandemic that travel restrictions are going to mean anything. But they can mean something, as a temporizing activity.

Gebelhoff: What should the average person be doing right now about coronavirus?

Fauci: It's a good question. 1) They should realize at this point, it is a low risk. And 2) that risk can change, so pay attention to what's going on [and] to the ... announcements coming from the CDC. ... The things that you do for influenza — get vaccinated, wash your hands, avoid crowded places — are exactly the same things that you would do if we did get coronavirus here. So the question is, should we do anything different from what we're already doing? No. Should we all be wearing a mask? Absolutely not.

Read more:

[The Post's View: The virus that shook China's system](#)

[Chen Guangcheng: Warning: Chinese authoritarianism is hazardous to your health](#)

[David Ignatius: The coronavirus outbreak shows the vulnerability of the 'Chinese model'](#)

[John M. Barry: Can this virus be contained? Probably not.](#)

[John Pomfret: The coronavirus reawakens old racist tropes against Chinese people](#)



[Robert Gebelhoff](#)

Robert Gebelhoff is an assistant editor for The Post's Opinions section. He has been with The Post since 2015.[Follow](#)

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 20:18:24 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Potential Treatment Strategy to Reduce Mortality Caused by Coronavirus Infection

NIAID inquiries, Please

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Monday, February 10, 2020 3:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Potential Treatment Strategy to Reduce Mortality Caused by Coronavirus Infection

Dear Dr. Fauci:

One effective way to get things done is through the individuals like you at the frontline with authorities. I know that you are very busy, and I am sorry to bother you. You probably already knew what I'm going to say and appear to be so relaxed.

With the significant concern for the quick spread of coronavirus infection, I would like to propose a cell-based immunomodulation strategy to reduce the "cytokine storm", the main pathophysiological cause for the mortality. The scientific rationale regarding this strategy has been partially discussed in an article entitled "Extending the Horizon of Cell Based Immunotherapy by Understanding the Mechanisms of Action of Photopheresis" and other related articles on this topic.

Several potential treatment modality could be derived from this concept if more laboratory and clinical data support this motion, which include : (1) ozone therapy (withdraw about 50 ml – 100 ml blood from patient in transfusion bag, mixing with small amount of ozone ex vivo and re-infuse back to patient in 30 minutes); (2) Cupping therapy (medically induced subcutaneous hemorrhage by heat and vacuums effects) to expose self antigens to the abundant dendritic cells in the subcutaneous tissue in order to reinforce the self antigen tolerance. The best timing for these interventions in theory would be at the

period of fever, viremia stage. These simple approaches can be incorporated with the other medical treatments and supportive care.

I cannot be certain, but want to help as a holistic physician. Thank you very much for reading this email and providing your insight as well as help.

Sincerely,

Ching Y. Voss, M.D.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 20:10:11 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Invitation to Speak at US-Asia Institute Event: February 26, Washington DC

Sorry. Cannot do. Congressional Hearing.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Zev Moses <zev.moses@usasiainstitute.org>
Sent: Monday, February 10, 2020 2:21 PM
To: Oplinger, Anne (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Subject: Invitation to Speak at US-Asia Institute Event: February 26, Washington DC

Good afternoon,

The US-Asia Institute would like to formally invite Director Dr. Anthony Fauci to speak at an event on February 26 in Rayburn House Office Building, Room 2253, at 1:00 pm. Our formal invitation is attached.

This event will focus on the public health impacts of the novel coronavirus, the facts on the ground, trajectory of the virus, and work to contain the outbreak. The event aims to educate Congressional staff on these topics and to dispel rumors associated with the virus. We believe that Director Dr. Fauci's current research is vital to supporting productive and informative dialogue.

Please let us know if Director Dr. Fauci, or another NIAID representative, is available to participate in this event. We would be honored to host him or others from NIAID and our audience would be extremely interested to learn from your agency's research.

Sincerely,
Zev Moses

--
Zev Moses | Director, International & Government Affairs
US-Asia Institute
232 East Capitol St. NE
Washington, D.C. 20003
202-544-3181
www.usasiainstitute.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 19:19:42 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Invitation to Speak at the March 13-15 Trilateral Commission Meeting in Washington, D.C.
Attachments: Dr. Anthony Fauci - Trilateral Plenary Meeting Speaking Invitation.pdf

Let us discuss. We do not need to bring before the OD AM group. I would like to do this if possible. It is an invitation from Meghan O'Sullivan who was one of the security crew from Bush 43.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Richard Fontaine <rfontaine@trilateral.org>
Sent: Monday, February 10, 2020 11:30 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Meghan O'Sullivan (b) (6) Torrey Taussig <ttaussig@trilateral.org>
Subject: Invitation to Speak at the March 13-15 Trilateral Commission Meeting in Washington, D.C.

Dear Dr. Fauci,

The Trilateral Commission will hold its invitation-only annual plenary meeting in Washington, D.C., on March 13-15, 2020. I would like to invite you to participate in a conversation at the meeting on responding to the coronavirus and global pandemics.

As you may know, the Trilateral Commission was launched by David Rockefeller in 1973 to think through the shared challenges and leadership responsibilities of the three principal industrialized democratic areas of the world: Europe, North American, and Japan (now Asia). Today, the Commission believes its original mission of bringing democratic countries together to tackle international challenges should once again be a major priority for our country and our partners. This year's plenary meeting is a major, three-day gathering of our global membership during which we will explore the theme "Democracy and Capitalism at a Crossroads."

Your participation would make a great difference if you are available. Attached to this email you will find an invitation from North American chair Meghan O'Sullivan. Please do let us know if you have any questions about the event or your potential role in it, and we hope that you are able to accept our invitation.

Best wishes,

Richard

Richard Fontaine
Executive Director
Trilateral Commission - North America

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 18:52:31 +0000
To: Strauss, Eric M.
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Heat kills novel Coronavirus

Eric:

The following is all on background. Coronaviruses in general tend to circulate and infect predominantly in the winter season (Northern and Southern hemispheres have opposite seasons). We do not know for sure why this is the case; however, many believe that the enclosed spaces in winter (mostly indoor because it is cold) allows better spread of a respiratory borne virus. Also, some viruses tend to thrive in cold, dry weather as opposed to warm, moist weather. Remember, however, that when it is summer here, it is winter in Australia and Argentina. This may be the genesis of the information given to President Xi and President Trump that the virus may “go away” in the warm weather. However, this is a brand new virus with which we have no prior experience and it is entirely conceivable that seasonal changes will not have any impact on the spread. Hope that this is helpful.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Sent: Monday, February 10, 2020 12:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Heat kills novel Coronavirus

Dr. Fauci:

We've been seeing a lot about people saying the heat will kill the novel coronavirus? Is this medically sound?

Trump discussed Coronavirus briefly: He said he had a long talk with President Xi two nights ago, and the Chinese president told him "the heat generally kills this kind of virus."

The president claimed the virus will go away in April as the seasons change: "The virus that we're talking about having to do a lot of people. We think that goes away in April with the heat," he said.

Eric M. Strauss, ABC News

Managing Editor, Medical Unit

www.ericmstrauss.com

Phone: 212-456-2016

Connect on Social: T/I/F = @ericMstrauss

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 18:08:29 +0000
To: Jon LaPook
Subject: FW: "Coronavirus is airborne, Chinese official confirms"
Attachments: Amoy Gardens and SARS.pdf

Jon:

Thanks for the note. See attachment for our future discussion.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6)>
Sent: Monday, February 10, 2020 10:08 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: amb@cbsnews.com; Kevin Finnegan <kpf@cbsnews.com>; Alturo Rhymes <RhymesA@cbsnews.com>; Jay Shaylor <Shaylor@cbsnews.com>; CBS LaPook <lapookj@cbsnews.com>
Subject: "Coronavirus is airborne, Chinese official confirms"

Hi Tony,

I need a Fauci brain dump.

You may have seen this:

https://www.nzherald.co.nz/world/news/article.cfm?c_id=2&objectid=12307276

Is this news? Don't we already know that the virus spread via droplet transmission? This article says aerosol transmission means "it can float a long distance to the air and cause infection later when it is breathed in." That makes it sound like the kind of spread that happens with measles, where the virus can linger in a room and infect somebody 2 hours after somebody with measles leaves the room.

Tomorrow, I will be giving an hour and a half of affiliate debriefings on this virus. So we will be reaching millions of people. I'd love to get the latest and greatest public health message. Incidentally, Howard Zucker and the infectious disease folks at NYU Langone are very concerned about overloading our emergency rooms with patients who have upper respiratory infection symptoms. What is the right message? If somebody calls thinking they have coronavirus, do you tell them to come in – risking infection of others? Do they stay home and wait for symptoms to get worse? Of course, it would be great if you could send them a kit and happen to home testing. But that's nowhere in the near future, right?

Thanks,
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 12:54:14 +0000
To: Sciutto, Jim
Subject: RE: Long time, no see!

Jim:

Thanks for the note. All is well here except that I am not getting much sleep - coronavirus 24/7. I look forward to being on your show.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Sciutto, Jim <Jim.Sciutto@cnn.com>
Sent: Monday, February 10, 2020 7:43 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Long time, no see!

Glad to have you on the show today. Looking forward. Hope all is well. Jim

Jim Sciutto
Newsroom Anchor & Chief National Security Correspondent
CNN
Email: jim.sciutto@cnn.com
Mobile: (b) (6)
Twitter: @jimsciutto

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 11:18:00 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Awwad, David (NIH/NIAID) [C]
Subject: FW: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

We did this before, but we cannot do it at 7:30 AM (b) (6). If they want to do it later in the day and we can fit them in, then fine. If not, that is OK too. Not the highest priority

From: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>
Sent: Monday, February 10, 2020 6:05 AM
To: Awwad, David (NIH/NIAID) [C] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Oplinger, Anne (NIH/NIAID) [E] (b) (6)>; Richa Sharma (WION) <Richa.sharma@zeemedia.esselgroup.com>
Subject: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Dear Anthony S. Fauci,

M.D., NIAID Director

Greetings from WION!

I would like to request for **your** time for an interview with us today for **10-15 minutes at 7:30 am Monday, in Maryland, USA via Skype.**

It's regarding the update in the story of Coronavirus - The World Health Organization chief says there have been 'concerning instances' of onward transmission of coronavirus among people who hadn't been to China.

Waiting for your confirmation.

CLICK HERE TO WATCH WION LIVE :

<https://www.wionews.com/live-tv>

[Live TV, News | wionews.com](#)

© 1998-2019 Zee Media Corporation Ltd (An Essel Group Company), All rights reserved.

www.wionews.com

Look forward hearing from you .

Regards

Latika Chugh

WION TV , India

From: Awwad, David (NIH/NIAID) [C] (b) (6)>
Sent: Thursday, February 6, 2020 6:41 PM
To: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>; KUMAR SUNNY <KUMAR.SUNNY@zeemedia.esselgroup.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Oplinger, Anne (NIH/NIAID) [E] (b) (6)>; Richa Sharma (WION) <Richa.sharma@zeemedia.esselgroup.com>
Subject: RE: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Our pleasure. Thank you again.

David

David Awwad, Contractor
Customer Services Branch, NIH\NIAID\OCICB
NTT DATA Services Federal, LLC

Phone: (b) (6)
(b) (6)

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>
Sent: Thursday, February 6, 2020 8:06 AM
To: Awwad, David (NIH/NIAID) [C] <(b) (6)>; KUMAR SUNNY <KUMAR.SUNNY@zeemedia.esselgroup.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] <(b) (6)>; Oplinger, Anne (NIH/NIAID) [E] <(b) (6)>; Richa Sharma (WION) <Richa.sharma@zeemedia.esselgroup.com>
Subject: Re: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

David,
Many thanks for the Interview.

He really added value in our show.

We look forward to have his presence in future on WION.

Regards
Latika Chugh

From: Awwad, David (NIH/NIAID) [C] <(b) (6)>
Sent: Thursday, February 6, 2020 5:00 PM
To: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>; KUMAR SUNNY <KUMAR.SUNNY@zeemedia.esselgroup.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] <(b) (6)>; Oplinger, Anne (NIH/NIAID) [E] <(b) (6)>; Richa Sharma (WION) <Richa.sharma@zeemedia.esselgroup.com>
Subject: RE: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Thank you much.

From: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>
Sent: Thursday, February 6, 2020 6:29 AM
To: Awwad, David (NIH/NIAID) [C] <(b) (6)>; KUMAR SUNNY <KUMAR.SUNNY@zeemedia.esselgroup.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] <(b) (6)>; Oplinger, Anne (NIH/NIAID) [E] <(b) (6)>; Richa Sharma (WION) <Richa.sharma@zeemedia.esselgroup.com>
Subject: Re: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Dear David,

It will be **live** Interview on WION with Dr. Fauci at 7 am Maryland Time for 10 -15 minutes only on Skype.

My colleague **Mr. Sunny** (marked in email) will patch the Skype sharp in 30 minutes from now.

Also, We have send you Skype Request from WION Skype Id some hours ago. I request you to please add us.

Regards
Latika Chugh

From: Awwad, David (NIH/NIAID) [C] <(b) (6)>
Sent: Thursday, February 6, 2020 4:54 PM
To: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Oplinger, Anne (NIH/NIAID) [E] (b) (6)>
Subject: RE: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Let me know if you would like to connect a couple minutes earlier. I am on standby.

David
(b) (6) (cell)

David Awwad, Contractor
Customer Services Branch, NIH\NIAID\OCICB
NTT DATA Services Federal, LLC
Phone: (b) (6)
(b) (6)

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>
Sent: Wednesday, February 5, 2020 9:25 AM
To: Awwad, David (NIH/NIAID) [C] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Barasch, Kimberly (NIH/NIAID) [C]

(b) (6); Oplinger, Anne (NIH/NIAID) [E] (b) (6)
Subject: Re: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Thanks
See you tomorrow

Latika : (b) (6)

Get [Outlook for Android](#)

From: Awwad, David (NIH/NIAID) [C] (b) (6)
Sent: Wednesday, February 5, 2020 7:50:26 PM
To: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Oplinger, Anne (NIH/NIAID) [E] (b) (6)
Subject: Re: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Skype Handle: Live:niaidithelp or niaidithelp@outlook.com

David: (b) (6)

Sent from my iPhone

On Feb 5, 2020, at 9:16 AM, Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com> wrote:

Yes,

It completely fine with us.

Our Skype Id - wion record. Please share your Skype id with us.

We will be online at **7 AM ET TIME WHICH WILL BE 5:30 PM OUR TIME IN IST.**

Regards
Latika Chugh
Producer , Wion
India

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 5, 2020 7:35 PM
To: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Awwad, David

(NIH/NIAID) [C] [REDACTED] (b) (6)>; Oplinger, Anne (NIH/NIAID) [E]

[REDACTED] (b) (6)>

Subject: FW: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

Dr. Fauci can do a skype interview Thursday morning 7 am – 7:15 am ET by skype. Please let us know asap if that works.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

[REDACTED] (b) (6)

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Latika Chugh (WION) <latika.chugh@zeemedia.esselgroup.com>

Sent: Tuesday, February 4, 2020 5:15 AM

To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>

Cc: Wion Guest Relations <wion.guestrelations@zeemedia.esselgroup.com>

Subject: REQUEST FOR A TV INTERVIEW ON WION TV INDIA

**Dear Anthony S. Fauci,
M.D., NIAID Director**

Greetings from WION!

World Is One News (WION) is an international English news channel from the Zee Media Group, India's premier television brand. WION is uniquely positioned as the 'Global Voice of India', presenting its own perspective on international issues of critical significance. WION is the preferred channel for most opinion makers across the world as they happily attend our shows bringing in credible viewpoints on many issues. WION is currently available in India, Indonesia, The Republic of Philippines, Australia, Vietnam, Hong Kong, UAE, Malaysia, Singapore and South Africa etc.

WION's shows have featured Indian Political scenario & global leaders speaking on issues facing their country and the world in general.

I would like to request for **your** time for an interview with us anytime soon today for **10-15 minutes**. We usually conduct Interview via **Skype**. Request you to share your Skype Id.

It's regarding CORONAVIRUS.

Please let us know when is the best time for you to join us via Skype. Waiting for your confirmation.

CLICK HERE TO WATCH WION LIVE :

<https://www.wionews.com/live-tv>

[Live TV, News | wionews.com](https://www.wionews.com)

© 1998-2019 Zee Media Corporation Ltd (An Essel Group Company), All rights reserved.

www.wionews.com

Look forward hearing from you .

Regards

Latika Chugh

WION TV , India

Zee Disclaimer: Confidentiality / Proprietary Note: This communication is confidential /proprietary and is intended for use only by the addressee. Zee Media Corporation Ltd. accepts no responsibility for any mistransmission of, orinterference with, this communication

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 00:49:33 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: CNN Interview CONFIRMATION: Dr. Anthony Fauci

Thanks.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Sunday, February 9, 2020 7:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Fwd: CNN Interview CONFIRMATION: Dr. Anthony Fauci

Sent from my iPhone

Begin forwarded message:

From: "Griffin, Janelle" <Janelle.Griffin@turner.com>
Date: February 9, 2020 at 5:54:23 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)
Cc: "Stover, Kathy (NIH/NIAID) [E]" (b) (6), "Routh, Jennifer (NIH/NIAID) [E]" (b) (6), "Akinso, Woleola (NIH/OD) [E]" (b) (6), "Greene, Nyja" <Nyja.Greene@turner.com>
Subject: CNN Interview CONFIRMATION: Dr. Anthony Fauci

Hello,

We're all set for tomorrow! 😊

Dr. Fauci is confirmed for a live segment at 10:15a et on Newsroom w/Poppy Harlow & Jim Sciutto.

Please ensure he's seated no later than 10:05a et. (the show is aware that Dr. Fauci has a hard at 10:20a et)

Nyja Greene, cc'd on this email, will be your Atlanta based show point of contact tomorrow.

Any issues or changes please don't hesitate to reach out to her in the morning.

Monday's segment will focus on latest Coronavirus developments: Dr. Fauci covered the SARS outbreak almost 17 years ago- from what he's seeing now with the Coronavirus, how bad do think this could become? How does the Coronavirus compare/contrast with others like Ebola or Zika? How effective are quarantines in situations like this? What, if any, precautions should we be taking right now in America? Any thoughts/talking points you can send over from Dr. Fauci evening would be super helpful.

Patricia- thank you sooo much for all of your help with organizing. We really appreciate it and look forward to Dr. Fauci joining the show.

From: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Sent: Saturday, February 8, 2020 1:04 PM
To: Griffin, Janelle <Janelle.Griffin@turner.com>
Cc: Stover, Kathy (NIH/NIAID) [E] <[REDACTED] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] <[REDACTED] (b) (6)> Akinso, Woleola (NIH/OD) [E] <[REDACTED] (b) (6)>
Subject: Re: CNN Interview Request: Dr. Anthony Fauci

Ok thx

Sent from my iPhone

On Feb 8, 2020, at 12:54 PM, Griffin, Janelle <Janelle.Griffin@turner.com> wrote:

Great- thank you!

Let's keep things for a segment at 10:15a on Monday.

I'll be back in touch after my 6p show planning conference call Sunday evening.

Thank so much Patricia 😊

From: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Sent: Saturday, February 8, 2020 12:53 PM
To: Griffin, Janelle <Janelle.Griffin@turner.com>
Cc: Stover, Kathy (NIH/NIAID) [E] <[REDACTED] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] <[REDACTED] (b) (6)> Akinso, Woleola (NIH/OD) [E] <[REDACTED] (b) (6)>
Subject: Re: CNN Interview Request: Dr. Anthony Fauci

We can make the 9 am hour work too. Pls let us know ASAP so I can make sure our studio is available. When will you have a final answer?

My cell is [REDACTED] (b) (6) and am always on email which is better for me.

Sent from my iPhone

On Feb 8, 2020, at 12:48 PM, Griffin, Janelle
<Janelle.Griffin@turner.com> wrote:

That's great- thanks Patricia!
We'll add him to our calendar for 10:15a et.

If we needed to move him his segment to the 9a et hour would
that also work?

May I have your cell number for my records?

From: Conrad, Patricia (NIH/NIAID) [E]
(b) (6)>
Sent: Saturday, February 8, 2020 12:46 PM
To: Griffin, Janelle <Janelle.Griffin@turner.com>
Subject: Fwd: CNN Interview Request: Dr. Anthony Fauci

Hi Janelle

We can make this work - it would need to be from between 10
am - 1020 am hard stop.

Will that work?

It would need to be from our NIH Readycam studio with
Videolink

Let me know if that works

From: Griffin, Janelle
<Janelle.Griffin@turner.com>
Sent: Saturday, February 8, 2020 11:33 AM
To: Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: CNN Interview Request: Dr. Anthony

Fauci

Importance: High

Good morning Dr. Fauci,

I hope this email finds you doing well.

I'm reaching out on behalf of Newsroom w/Poppy Harlow & Jim Sciutto hoping you can join for an interview.

Are you available to join CNN this Monday

February 10th in the 10a et hour?

This would be live for about 5-7 minutes to discuss developments regarding the coronavirus.

Please feel free to contact me via email or at (404) 452-7769 to let me know.

Thanks for your time- I look forward to hearing from you soon.

Janelle Griffin-Butts

Editorial Producer, **CNN**

Email: janelle.griffin@turner.com | Twitter:

@janellegCNN

From: (b) (6)
Sent: Sun, 9 Feb 2020 16:36:38 -0500
To: autotell|
Subject: Re: Help Re: Novel Rx for Coronavirus

Thanks, Andy.
Best regards,
Tony

On Feb 9, 2020, at 4:29 PM, autotell| (b) (6) > wrote:

Thank you my friend, hope it leads to something good for patients and the public. I was at a meeting of the "Philosophical Society of Texas" this week end and meet with a lot of Bush alums like Don Evans and Margaret Spellings etc and Margaret was commenting on the coronavirus scare and how fortunate we are to have you there at NIH looking after us!! If you ever decide to relocate to Texas you have a fan club here!
All my best
Andy

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, February 9, 2020 7:24 AM
To: autotell| (b) (6) >
Subject: RE: Help Re: Novel Rx for Coronavirus

Andy:

Thanks for the note. I will take a look at this and more importantly, I will run it by the people here at NIAID who are running the nCoV research initiative. I will get back to you with their and my assessment. I hope that all is well with you. We are doing a lot of late nighters here. Feels like my internship. ☐☐

Best regards,
Tony

From: autotell| <(b) (6)t>
Sent: Friday, February 7, 2020 2:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Xiaokui Zhang (b) (6) >; Robert Hariri (b) (6) >
Subject: Help Re: Novel Rx for Coronavirus

Tony

Greetings. Always proud to see you at the White House (with Alex) leading the fight against this latest infectious disease threat

(b) (4)

(b) (4)



I trust this email finds my Paisano happy and content as you continue to be a gift to this nation and the world. Please let me know you received this email.

My best to you and your family. Hope our paths cross soon

Andy

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 18:23:24 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: Investigational compound remdesivir, developed by UAB and NIH researchers, being used for treatment of novel coronavirus

WOW! I did not know that. Good talking point for press conferences.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Sunday, February 9, 2020 1:13 PM
Subject: Investigational compound remdesivir, developed by UAB and NIH researchers, being used for treatment of novel coronavirus

Investigational compound remdesivir, developed by UAB and NIH researchers, being used for treatment of novel coronavirus

[by Savannah Koplou](#)

- February 07, 2020
- [Print](#)
- [Email](#)



Richard Whitley, M.D., Distinguished Professor at UAB and principal investigator of the U19 grant

The investigational drug remdesivir, developed through research conducted through the [Antiviral Drug Discovery and Development Center](#), or AD3C, and centered at the [University of Alabama at Birmingham](#), is being used to treat select infected patients in the United States and in China who have been affected by the outbreak of novel coronavirus (2019-nCoV).

UAB was awarded a \$37.5 million, [five-year U19 grant](#) from the [National Institute of Allergy and Infectious Diseases Centers of Excellence for Translational Research](#) to study and develop treatment for high-priority emerging infections. Work has been taking place in earnest to develop drugs for emerging influenza, flaviviruses (dengue, West Nile virus and Zika), coronaviruses that cause SARS and MERS, and alphaviruses such as Venezuelan equine encephalitis virus and chikungunya. The grant is a multi-

institutional collaboration to accelerate drug discovery for these emerging infections and is a public-private partnership between academic institutions and Gilead Sciences.

Remdesivir, developed to treat the coronavirus causing MERS, was found to have significant activity against the 2019-nCoV strain when the outbreak began in the Chinese city of Wuhan. Importantly, remdesivir had demonstrated efficacy in treating other medically important coronaviruses MERS and SARS in cell culture and animal models. Based on the compassionate plea requests of treating physicians in the United States, Gilead Sciences released remdesivir for use in a few patients, although the drug has not yet been tested for safety or efficacy in these diseases. “The release of remdesivir for safety and efficacy studies is a major accomplishment for the AD3C – namely the U19 grant – as it shows significant and swift advance of antiviral drugs to help treat and respond to emerging infectious disease outbreaks on an international scale and, importantly, to anticipate the introduction of these infections in the United States,” said Richard Whitley, M.D., Distinguished Professor at UAB and principal investigator of the U19 grant.

[WATCH: UAB infectious disease experts provide information on the 2019 novel coronavirus.](#)

Gilead Sciences and supporting researchers and clinicians are working with health authorities from the World Health Organization and in China to establish a placebo-controlled study to determine whether remdesivir is safe and effective in treating 2019-nCoV.

“This is a prime example of how the research we are conducting at UAB plays a critical role in treating patients on a global scale and our contribution of substantial scientific advances.”

– Richard Whitley, M.D., UAB Distinguished Professor

“The collaboration between UAB, our colleagues at Southern Research, Vanderbilt University and the University of North Carolina, along with our pharmaceutical partner Gilead Sciences, is indicative of our collaborative approach to respond to outbreaks in real time, and in helping communities worldwide fight 2019-nCoV. This is a prime example of how the research we are conducting at UAB plays a critical role in treating patients on a global scale and our contribution of substantial scientific advances,” Whitley continued.

Whitley expressed that the potential for mutation of 2019-nCoV means that UAB’s AD3C and partners will need to build backup molecules for potential testing and treatment in the near future.

The World Health Organization has declared the 2019-nCoV outbreak a “public health emergency of international concern.”

UAB is the lead institution for AD3C and research conducted; but the team unifies scientists experienced in virology, viral immunology, pathogenesis, medicinal chemistry and translation to human disease from UAB, University of North Carolina, Vanderbilt University, Emory University, Washington University, The University of Texas Medical Branch, Southern Research, the Emory Institute of Drug Discovery, the University of Colorado, Denver, and Oregon Health & Science University.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 18:20:45 +0000
To: Liz Szabo
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Plumbing as possible means of spread of coronaviruses
Attachments: Amoy Gardens and SARS.pdf

Liz:

Thanks for the note. I do not know enough about the plumbing system on the cruise ships to make any meaningful comments, certainly not any comments that could be attributable to me. And so, I will pass on this one, The best person to comment or opine on this would be Mart Cetron of CDC. FYI, in case you do not have it in front of you, I am attaching the original NEJM article on the Amoy Gardens Apartment story in Hong Kong with SARS.

Best regards,
Tony

From: Liz Szabo <LSzabo@kff.org>
Sent: Saturday, February 8, 2020 7:21 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Plumbing as possible means of spread of coronaviruses

Hi Dr. Fauci,

I hope you're doing well. I know you must be very busy.

Our editor, Dr. Elizabeth Rosenthal, is wondering whether the new coronavirus might be spreading through plumbing on the cruise ship? She sent me these links, below, about how plumbing played a role in spreading SARS in the Amoy Gardens apartment complex in Hong Kong. Libby lived in China during the SARS outbreaks and remembers that the sinks there don't have the typical U-bend trap that sinks have here, which allows sewer gases and unpleasant odors to come through.

If plumbing is a risk for spreading coronaviruses, what could be done to protect passengers on cruise ships?

I'd love to hear your thoughts on this, even if just by email.

Thanks for your time.

Liz Szabo
Kaiser Health News
571-201-9009

<https://www.cbsnews.com/news/leaky-plumbing-linked-to-sars-spread/>

<https://www.cnn.com/2013/02/21/world/asia/sars-amoy-gardens/index.html>

<https://plumbingconnection.com.au/new-report-proves-plumbing-link-to-sars/>

<https://www.infectioncontrolday.com/personal-protective-equipment/sars-and-plumbing-role-sewage-plays-spreading-disease>

https://jamanetwork.com/journals/jama/fullarticle/2761044?guestAccessKey=f61bd430-07d8-4b86-a749-bec05bfff65&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=020720

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 17:59:10 +0000
To: Tabak, Lawrence (NIH/OD) [E]
Cc: Schwetz, Tara (NIH/OD) [E];Erbelding, Emily (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [C] (b) (6)
Subject: RE: NCATs request re. Coronavirus

Larry:

(b) (5)

Best,
Tony

From: Tabak, Lawrence (NIH/OD) [E] (b) (6) >
Sent: Sunday, February 9, 2020 12:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Schwetz, Tara (NIH/OD) [E] (b) (6) >
Subject: NCATs request re. Coronavirus

Tony,

(b) (5)

Thanks,
Larry

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 17:53:04 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: CNN Anderson Cooper Full Circle Request- Dr. Anthony Fauci

OK. Thanks.

From: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6) >
Sent: Sunday, February 9, 2020 12:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Fwd: CNN Anderson Cooper Full Circle Request- Dr. Anthony Fauci

I am working on this.

Sent from my iPhone

Begin forwarded message:

From: "Varon, Sophie" <Sophie.Varon@turner.com>
Date: February 9, 2020 at 12:30:31 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" [REDACTED] (b) (6) >, "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6)
Subject: CNN Anderson Cooper Full Circle Request- Dr. Anthony Fauci

Hello Dr. Fauci and Patricia,

I hope you're both doing well.
I'm reaching out to see if Dr. Fauci could be available for an interview with Anderson Cooper on Monday for his CNN digital program, Full Circle. Full Circle is an interesting platform because it allows us to take live viewer questions. This taped interview would air on Tuesday at 5PM and Anderson could tape tomorrow in the 4PM hour or after 5:45PM.

The topic is of course the Coronavirus.

Thank you for considering this request!

Sophie Varon
Editorial Producer, CNN AC360
cell- [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 17:52:22 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: CNN Anderson Cooper Full Circle Request- Dr. Anthony Fauci

If we can do this, I would be happy to.

From: Varon, Sophie <Sophie.Varon@turner.com>
Sent: Sunday, February 9, 2020 12:30 PM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: CNN Anderson Cooper Full Circle Request- Dr. Anthony Fauci

Hello Dr. Fauci and Patricia,

I hope you're both doing well.

I'm reaching out to see if Dr. Fauci could be available for an interview with Anderson Cooper on Monday for his CNN digital program, Full Circle. Full Circle is an interesting platform because it allows us to take live viewer questions. This taped interview would air on Tuesday at 5PM and Anderson could tape tomorrow in the 4PM hour or after 5:45PM.

The topic is of course the Coronavirus.

Thank you for considering this request!

Sophie Varon

Editorial Producer, CNN AC360

cell- (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 17:51:21 +0000
To: Hall, Bill (HHS/ASPA)
Subject: FW: CNNI Interview with Dr. Anthony Fauci,

Bill:

This link below is for an interview that I gave for CNN International this morning. As we all know, it makes such a big difference when the interviewer knows the subject and asks good questions that this interviewer did. Would that they were all like her.

Best regards,
Tony

From: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Sent: Sunday, February 9, 2020 12:30 PM
To: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: RE: CNNI Interview Request: Dr. Anthony Fauci,

We are so glad to!

Here is the clip <https://we.tl/t-B0kVJSyQVB>

All the best,

Joanna

From: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)>
Sent: 09 February 2020 16:15
To: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Re: CNNI Interview Request: Dr. Anthony Fauci,

My pleasure- so glad we could make it work. Please do send us the the video segment

Best ,
Patty.

Sent from my iPhone

On Feb 9, 2020, at 11:06 AM, Hynds, Joanna (NE) <Joanna.Hynds@turner.com> wrote:

Dear Mr Fauci,

I just wanted to thank you for your accommodation at such short notice for the earlier interview. I do apologise for the miscommunication on my part.

We really enjoyed having you on the show!

Thanks too to Patricia, for helping coordinate this all at last minute.

I hope you both have a great evening.

Many thanks again for your patience and understanding.

If you would like a video segment of your hit I will gladly send you it on request.

Best,

Joanna

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: 09 February 2020 14:26
To: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Cc: Pfeifer, Hazel <Hazel.Pfeifer@turner.com>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: CNNI Interview Request: Dr. Anthony Fauci,

Do you have the hit time and contact info please send ASAP.

Sent from my iPhone

On Feb 9, 2020, at 8:38 AM, Hynds, Joanna (NE) <Joanna.Hynds@turner.com> wrote:

Perfect – we really appreciate this.

I will get you these details ASAP.

Does Dr Fauci need a car?

Best,

Joanna

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: 09 February 2020 13:33
To: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Cc: Pfeifer, Hazel <Hazel.Pfeifer@turner.com>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: CNNI Interview Request: Dr. Anthony Fauci,

Adding Dr Fauci here

He can come to the WDC CNN studio. Please send us the exact live hit time as well as the studio address and on-site contact name, number and cell number ASAP. Dr Fauci cell is (b) (6) and you have mine.

Thank you.

Sent from my iPhone

On Feb 9, 2020, at 8:21 AM, Hynds, Joanna (NE) <Joanna.Hynds@turner.com> wrote:

Dear Patricia,

Just following up from our phone conversation, unfortunately I won't be able to facilitate a StudioGo truck for this interview.

We are still really keen to get Dr Fauci on the show – will he be able to come to the bureau?

I will be able to book him a car if he needs.

Let me know what suits,

Best,

Joanna

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: 09 February 2020 13:00
To: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Subject: Re: CNNI Interview Request: Dr. Anthony Fauci,

For the trick- the location is northwest Washington DC. Near American university.

Sent from my iPhone

On Feb 9, 2020, at 7:51 AM, Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6) > wrote:

Please call me ASAP at [REDACTED] (b) (6) for this request.

Sent from my iPhone

Begin forwarded message:

From: "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6) >
Date: February 9, 2020 at 7:08:54 AM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" [REDACTED] (b) (6)
Subject: Fwd: CNNI Interview
Request: Dr. Anthony Fauci,

Sent from my iPhone

Begin forwarded message:

From: "Hynds, Joanna (NE)" <Joanna.Hynds@turner.com>
Date: February 9, 2020 at 6:06:15 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" [REDACTED] (b) (6) >
Cc: "Tejera, Isabel (Intern)" <isabel.Tejera@turner.com>, "Lovejoy, Hannah

(NE)"
<Hannah.Lovejoy@turner.com>

**Subject: CNNI
Interview Request: Dr.
Anthony Fauci,**

Dear Dr Fauci,

I hope you are well! I am reaching out from CNN International to enquire if you are available today to join us on **Connect the World** at **11aET** to discuss the coronavirus.

Might this be a possibility? It would be great to arrange this.

Background on CNN

- CNN International reaches more than 250 million households worldwide including in the US via DIRECTV.
- CNN International is the number one international TV news channel according to all major media surveys across Europe, the Middle East and Africa, the Asia

Pacific region
and Latin
America.

- In September 2019 [CNN.com](https://www.cnn.com) had 162 million unique readers globally per month and 114 million mobile readers a month, leading the BBC, Yahoo and New York Times.

Best,

Joanna Hynds

Planning Desk

CNN International

+ 44 207 693 1640

(office)

+ (b) (6) (cell)

joanna.hynds@turner.com

<image001.png>

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store,

retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks.

Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and

delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 17:34:16 +0000
To: Denise Ober
Subject: RE: HEART WRENCHING QUESTION! ❤️🇺🇸

The State Department and CDC travel alerts for China, which advise only absolutely essential travel, do not officially include Hong Kong and so there is no official restriction right now (but this could change), and there is no quarantine requirement upon returning from Hong Kong. However, this all could change quickly. (b) (6)

-----Original Message-----

From: Denise Ober (b) (6) >
Sent: Saturday, February 8, 2020 3:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: HEART WRENCHING QUESTION! ❤️🇺🇸

Dear Dr. Fauci,

I realize this is a long shot for you to answer this email. Please forgive me since I'm sure you are so extremely busy and so very importantly needed at this time. I do apologize for taking even a moment from your high demand schedule. But thought I'd try to reach out anyway in case you did see this.

I saw an interview recently you had with Dr. Baucher posted by JAMA. From your expertise and knowledge about the coronavirus thus far, if you had planned to travel to Thailand mid March via stop over at Hong Kong would you? (b) (6)

Thank you from my concerned heart!
Thank you for EVERYTHING you do and have done in the past!
Best to you,
Denise Ober
Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 17:26:01 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Erbelding, Emily (NIH/NIAID) [E];Auchincloss, Hugh (NIH/NIAID) [C] (b) (6);Barasch, Kimberly (NIH/NIAID) [C];Greg Folkers (b) (6);Marston, Hilary (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E]
Subject: FW: Help Re: Novel Rx for Coronavirus
Attachments: (b) (4) in 2019-CoV Proposal 07Feb2020.docx

Cristina:

This is not just your ordinary person writing to us. This is Dr. Andrew von Eschenbach, former Director of NCI and Former Commissioner of FDA. I have no idea if this proposal has any merit; however, please have someone go over it carefully and put together a response. Also, only if appropriate, and feasible, see if there is any way we can be of assistance to him. Thanks.

Best regards,

Tony

From: autotell | (b) (6)
Sent: Friday, February 7, 2020 2:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Xiaokui Zhang (b) (6)>; Robert Hariri (b) (6) (b) (6)
Subject: Help Re: Novel Rx for Coronavirus

Tony

Greetings. Always proud to see you at the White House (with Alex) leading the fight against this latest infectious disease threat. (b) (4)

(b) (4)

I trust this email finds my Paisano happy and content as you continue to be a gift to this nation and the world. Please let me know you received this email.

My best to you and your family. Hope our paths cross soon

Andy

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 17:17:07 +0000
To: Stover, Kathy (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]
Subject: RE: FOR ASF REVIEW: Draft responses to questions from Italian news agency

See my edits in red.

From: Stover, Kathy (NIH/NIAID) [E] (b) (6)>
Sent: Friday, February 7, 2020 2:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6)
Subject: FOR ASF REVIEW: Draft responses to questions from Italian news agency

Hi Dr. Fauci,

Below are draft responses to questions from a reporter with the Italian news agency ANSA. Please let me know if you have any suggested edits, and I'll move it along.

Thanks,
Kathy

Enrica Battifoglia
Science and Technology Head Editor
ANSA news agency (Italian news)
Enrica.Battifoglia@ansa.it

Expected place of publication: ANSA Science web page (www.ansa.it/scienza)

Dear Professor Fauci,

I am Enrica Battifoglia of the Italian news agency ANSA, I already have had the pleasure to interview you several times at the AIDS world conferences.

I would like to ask you some questions about Coronavirus 2019-nCoV, to be published on the ANSA Science web page (www.ansa.it/scienza), the main online science news resource in Italy with over 1.5M contacts each month. I am sure that your clarity and competence will be highly valuable to put some much-needed order among so many contrasting news and data, and would be much appreciated by our readers.

1. **Do the current available data allow to understand the threat level of coronavirus 2019-nCoV in terms of both lethality and diffusion speed, and about the possible evolution scenarios of the disease?**

There is much that we do not know about the novel coronavirus. Currently, there have been more than 37,000 confirmed cases in China, and China has reported more than 800 deaths. As you know, there have been three confirmed cases in Italy to date. **The reported case fatality rate (lethality) among the 37,000 cases that have come to the attention of the health care system is 2%. However, given that there are likely many more cases that are without symptoms or with minimal symptoms, the actual death rate is probably lower than 2%.**

It is impossible to predict how the virus will evolve. It is our hope that the extraordinary containment measures that China has implemented will help **prevent** the outbreak from becoming a global pandemic. But given that the virus is present in 27 countries to date and can be transmitted from person-to-person, it may take a foothold and **evolve into a global pandemic.**

2) **What exactly do we know about its modes of transmission, especially from people who do not yet have the symptoms?**

Again, there is much that we do not know about the novel coronavirus, including its specific transmission abilities. Based on initial findings that have been reported, we suspect its transmission is similar to influenza and other respiratory viruses, namely that is transmitted through respiratory droplets when an infected person coughs or sneezes, and by touching surfaces, such as door handles, that **recently** have virus on them and then touching your face. There have also been reports that the virus **is present in feces and vomit. However, it is still uncertain that the virus can be transmitted through this route.**

Traditionally, most viruses are transmitted when someone has symptoms. With the novel coronavirus; however, there appears to be asymptomatic transmission occurring. We do not know how many cases are being driven by asymptomatic transmission or by those with symptoms. Typically, viruses are largely transmitted by infected people experiencing symptoms.

3) **Are the genetic sequences provided by China enough to start working on a vaccine?**

The genetic sequences provided by China enabled researchers to quickly develop a diagnostic that is being used to determine whether someone is infected with the novel coronavirus. The genetic information has also been useful in work to develop a preventive vaccine. The National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health, is building on its experience with the SARS and MERS coronaviruses to better understand the virus as well as develop and test rapid point-of-care diagnostics, vaccines and treatments, including broad-spectrum antivirals and antibody therapies. In terms of vaccines specifically, we are

working with the biotechnology company Moderna and the Coalition for Epidemic Preparedness Innovation (CEPI) to develop a “messenger RNA” vaccine for the novel coronavirus. Other countries and companies are working to develop a vaccine as well.

4) What are the technical times to develop a working vaccine in terms of scientific research, and what are the approx times for the necessary legal certifications, and for industrial production and distribution?

In terms of our work with Moderna and CEPI to develop a vaccine, we anticipate having an experimental vaccine ready for Phase 1 clinical trials within 2 to 3 months. This Phase 1 clinical trial will involve administering the vaccine to a small number of healthy adults in the United States to see if it is safe and has some ability to induce an immune response. If that is successful and the outbreak has not ended, we will move to a larger Phase 2 clinical trial with the expectation of **proving the efficacy (or not) of the vaccine within 1 to 1.5 years. If efficacious, it will still take additional months to produce enough vaccine to distribute widely..**

In addition to this vaccine, NIAID is also supporting scientists and companies to develop other vaccine candidates.

5) 2019-nCov is the third Coronavirus aggressive for humans that has appeared in the East in the last 20 years and in 2009 the virus responsible for the flu pandemic too did come from China: what sort of preventive measures could be practicable to reduce the risk of repetition of these events?

To clarify, the 2009 H1N1 influenza virus was first reported in Mexico, not China.

Viruses affecting humans have occurred throughout history, from the Bubonic Plague to the 1918 flu. We cannot predict what emerging infectious diseases will occur nor prevent the unknown from occurring in the first place. What we can do is learn as much as we can about emerging viruses, so that we can rapidly develop safe and effective point-of-care diagnostics, treatments and vaccines to protect against infection.